QUINAZOLINONE DERIVATIVES

Abstract: A quinazolinone derivatives having poly(adenosine 5'-diphaspho-ribose)polymerase (PARP) inhibotory activity represented by the formula (I), wherein R<1> is optionally substituted cyclic amino groups or optionally substituted amino group, R<2> is substituent, n means an integer from 0 to 4, and L is lower akkylene or lower alkenylene, or its prodrug, or their salts.

Description: DESCRIPTION QUINAZOLLNONE DERIVATIVES Technical Field This invention relates to novel quinazolinone derivatives having pharmacological activity, to a process for their production and to a pharmaceutical composition containing the same. Background Art Poly(adenosine 5'-diphaspho-ribose)ρolymerase ["poly(ADP-ribose)polynerase" or "PARP", which is also sometimes called "PARS" for "ρoly(ADP-ribose)synthetase"] is an enzyme located in the nuclei of cells of various organs, including muscle, heart and brain cells. PARP plays a physiological role in the repair of strand breaks in DNA. Once activated by damaged DNA fragments, PARP catalyzes the attachment of up to 100 ADP-ribose units to a variety of nuclear proteins, including histones and PARP itself. Some quinazolinone derivatives having inhibitory activity of PARP have been known, for example, in WO95/24379, WO98/33802 and WO99/11624. Disclosure of the Invention This invention relates to novel quinazolinone compounds, which have pharmaceutical activity such as PARP inhibiting activity, to a process for their production, to a pharmaceutical composition containing the same and to a use thereof. One object of this invention is to provide the novel quinazolinone compounds, which have a PARP inhibiting activity. Another object of this invention is to provide a process for production of the quinazolinone compounds. A further object of this invention is to provide a pharmaceutical composition containing the quinazolinone compound as an active ingredient. Still further object of this invention is to provide a use of the quinazolinone compound for manufacturing a medicament for treating or preventing various diseases, or a method of treating or preventing various diseases by administering the quinazolinone compound in an effective amount to inhibit PARP activity. Thus, the present invention provides the following. [ 1 ] A compound of the formula: wherein R is optionally substituted cyclic amino groups or optionally substituted amino group, R 2 is substituent, n means an integer from 0 to 4, and L is lower alkylene or lower alkenylene, or its prodrug, or their salts. [2] The compound according to [1], wherein R 2 is halogen, nitro, amino, acylamino, aryl(lower)alkylamino, lower alkylamino, lower alkyl, lower alkynyl, lower alkoxy, acyl, or cyclic amino group optionally substituted with lower alkyl. [3] The compound according to [2], wherein R 1 is (1) cyclic amino group optionally substituted with one or more substituent(s) selected from the group consisting of halogen, cyano, hydroxy, amino, oxo, lower alkyl, lower alkenyl, lower alkynyl, aryl(lower)alkyl, aryl(lower)alkynyl, acyl, lower alkylsulfonyl, optionally substituted heteroaryl and optionally substituted aryl, or (2) amino optionally substituted with 1 or 2 substituent(s) selected from the group consisting of lower alkyl, aryl, heteroaryl(lower)alkyl, aryl(lower)alkoxycarbonyl and aryl(lower)alkyl optionally substituted with aryl or aryloxy. [4] The compound according to [3], wherein R 1 is cyclic amino group optionally substituted with optionally substituted heteroaryl or optionally substituted aryl. [5] The compound according to [4], wherein R 1 is cyclic amino group with saturated or unsaturated monocyclic group with one or more nitrogen atom(s), which is substituted with optionally substituted heteroaryl or optionally substituted aryl. [6] The compound according to [5], wherein R 1 is tetrahydropyridyl, piperidyl or piperazinyl, each of which is substituted with optionally substituted heteroaryl or optionally substituted aryl. [7] The compound according to any one of [4], [5] and [6], wherein substituent(s) of optionally substituted heteroaryl is lower alkyl, halogen, cyano or acyl, or substituent(s) of optionally substituted aryl is halogen, cyano, hydroxy, carboxy, nitro, amino, lower alkyl, hydroxy(lower)alkyl, lower alkoxy, lower alkyl thio, halo(lower)alkyl, lower alkylamino, acylamino, halo(lower)alkoxy, aryl, aryloxy, or acyl. [8] The compound according to [3], wherein R 1 is cyclic amino groups with saturated and unsaturated fused cyclic groups, which is substituted with optionally substituted lower alkyl. [9] The compound according to any one of [4], [5], [6], [7] and [8], wherein L is trimethylene. [10] The compound according to [9], which is selected from the group consisting of: (l) 5-chloro-2-[3-(4-phenyl-3,6-dihydro-l(2H)-pyridinyl)propyl]- 4(3H)-quinazolinone, (2) 2- { 3 -[4-(4-hydroxyphenyl)-3 , 6-dihydroρyridin- 1 (2H)-yl]ρropyl } - 4(3H)-quinazolinone, (3 ) 8-methy 1-2- { 3 - [4-(4-methoxyphenyl)-3 , 6-dihydro- 1 (2H)-pyridinyl]propyl } - 4(3H)-quinazolinone, (4) 8-chloro-2- { 3 -[4-(4-fluorophenyl)-3 ,6-dihydro- 1 (2H)-pyridinyl]propyl } - 4(3H)-quinazolinone, (5) 8-chloro-2- { ( lE)-3 -[4-(4-fluorophenyl)-3 , 6-dihydro- 1 (2H)-pyridinyl]- 1 -propenyl} - 4(3H)-quinazolinone, (6) 8-Chloro-2- { [4-(4-pyridinyl)-3 , 6-dihydro- 1 (2H)-pyridinyl] propyl } - 4(3H)-quinazolinone, (7) 2-{3-[4-(4-chlorophenyl)-l-piperazinyl]propyl}-4(3H)-quinazolinone, (8) 2-{3-[4-(4-pyridyl)-l-piperazinyl]propyl}-4(3H)-quinazolinone, (9) 2-[3-(l,4,5,6-Tetrahydrobenzo[f|isoquinolin-3(2H)-yl)propyl]- 4(3H)-quinazolinone, and (10) 8-methyl-2-[3-(l,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)propyl]- 4(3H)-quinazolinone. [11] A process for preparing a compound of the formula: wherein R 1 is optionally substituted cyclic amino groups or optionally substituted ammo group, R is substituent, n means an integer from 0 to 4, and L is lower alkylene or lower alkenylene, or its prodrug, or their salts, which comprises, (1) reacting the formyl group of the compound (II) of the formula: or its aminal derivative, or their salt, and imino group of the compound (IV) of the formula: R J -H or its salt, in the presence of a reducing agent to provide a compound of the formula: or its salt, in the above formulae, R 1 , R 2 , n and L are each as defined above, and L 1 is lower alkylene or lower alkenylene delating a methylene group from the end of the one defined in L, or (2) subjecting the compound (III) of the following formula: or its salt, to cyclization reaction in the presence of base to provide a compound of the formula: or its salt, in the above formurae, R 1 , R 2 , n and L are each as defined above. [12] A pharmaceutically composition comprising a compound of the formula: wherein R is optionally substituted cyclic amino groups or optionally substituted amino group, R 2 is substituent, n means an integer from 0 to 4, and L is lower alkylene or lower alkenylene, or its prodrug, or their pharmaceutically acceptable salts, and a pharmaceutically acceptable carrier, wherein said compound is present in an amount effective for inhibiting PARP activity. [13] The pharmaceutical composition of [12] for treating or preventing diseases ascribed by NMD A- and NO-induced toxicity. [14] The pharmaceutical composition of [12] for extending the lifespan or proliferative capacity of cells or altering gene expression of senescent cells [15] The pharmaceutical composition of [13] for treating or preventing tissue damage resulting from cell damage or death due to necrosis or apoptosis; neural tissue damage resulting from ischemia and reperfusion injury, neurological disorders and neurodegenerative diseases; neurodegenerative diseases; head trauma; stroke; Alzheimer's disease; Perkinson's disease; epilepsy; Amyotrophic Lateral Scleosis (ALS); Huntington's disease; schizopherenia; chronic pain; ischemia and nloss following hypoxia; hypoglycemia; ischemia; trauma; nervous insult; previously ischemic heart or skeleton muscle tissue; radiosensitizing hypoxic tumor cells; tumor cells from recovering from potentially lethal damage of DNA after radiation therapy; skin aging; atheroscleosis; osteoarthritis; osteoporosis; muscular dystrophy; degenerative diseases of skeletal muscle involving replicative senescence; age-related macular degeneration; immune senescence; AIDS; and other immune senescencediseases; inflammatory bowel disorders (e.g., colitis); arthritis; diabetes; endotoxic shock; septic shock; and tumor. [16] A method of inhibiting PARP activity comprising administering a compound of the formula: wherein R 1 is optionally substituted cyclic amino groups or optionally substituted amino group, R 2 is substituent, n means an integer from 0 to 4, and L is lower alkylene or lower alkenylene, or its prodrug, or their pharmaceutically acceptable salts, and a pharmaceutically acceptable carrier, wherein said compound is present in an amount effective for inhibiting PARP activity. The quinazolinone compounds of this invention can be represented by the following formula (I): [wherein R 1 is optionally substituted cyclic amino groups or optionally substituted amino group, R 2 is substituent, n means an integer from 0 to 4, and L is lower alkylene or lower alkenylene.] or its prodrug, or their salt. The compound (I) or its prodrug, or their salt can be prepared by the following processes. In the following formulae, compounds may be prodrugs or their salts. Process 1 (IN) (I) or its aminal derivative, or its salt or its salt or their salt [wherein, R 1 , R 2 , n and L are each as defined above, and L 1 is lower alkylene or lower alkenylene delating a methylene group from the end of the lower alkylene defined in L] In this process the compound (I) can be produced by reacting the formyl group of the compound (II) and imino or amino group of the compound (IN) in the presence of a reducing agent such as sodium cyanoborohydride, sodium borohydride, lithium cyanoborohydride, borane, diethylsilane, catalytic reduction with Raney nickel, or the like. This reaction preferably carried out in the acidic condition, such as the presence of acid (e.g., acetic acid, hydrogen chloride, trifluoroacetic acid). The reaction is usually carried out in a conventional solvent such as water, an alcohol (e.g., methanol, ethanol or isopropyl alcohol), ether (e.g., tetrahydrofuran, dioxane, diethylether), amide (e.g., Ν,Ν-dimethylformamide, N,N-dimethylacetamide), nitrile (e.g., acetonitrile), or any other organic solvent which does not adversely affect the reaction. The reaction may be usually carried out under cooling to heating since the reaction temperature is not critical. Process 2 (in) (I) or its salt or its salt [wherein, R 1 , R 2 , n and L are each as defined above.] In this process, the compound (I) can be produced by subjecting the compound (III) to cyclization reaction in the presence of base, such as inorganic bases, for example, an alkali metal [e.g., sodium or potassium], alkoxide, hydroxide, carbonate or bicarbonate thereof, or organic bases such as a trialkylamine [e.g., trimethylamine or triethylamine] or the like. The reaction is usually carried out in a conventional solvent such as water, an alcohol (e.g., methanol, ethanol or isopropyl alcohol), ether (e.g., tetrahydrofuran, dioxane, diethylether), amide (e.g., N,N~dimethylformamide, N,N-dimethylacetamide), nitrile (e.g., acetonitrile), or any other organic solvent which does not adversely affect the reaction. The reaction may be usually carried out under cooling to heating since the reaction temperature is not critical. Process 3 o alt [wherein, X is leaving group, R 2 a is cyclic amino group, R 1 , n and L are each as defined above.] In this process, the compound (I-a) or its salts can be produced by reacting the compound (IN) or its salt and compound (V) in the presence of base, such as inorganic bases, for example, an alkali metal [e.g., sodium or potassium], alkoxide, hydroxide, carbonate or bicarbonate thereof, or organic bases such as a trialkylamine [e.g., trimethylamine or triethylamine] or the like. The reaction is usually carried out in a conventional solvent such as an alcohol (e.g., methanol, ethanol or isopropyl alcohol), ether (e.g., tetrahydrofuran, dioxane, diethylether), amide (e.g., Ν,Ν-dimethylformamide, N,N-dimethylacetamide), nitrile (e.g., acetonitrile), or any other organic solvent which does not adversely affect the reaction. The reaction may be usually carried out under cooling to heating since the reaction temperature is not critical. Process 4 Reduction (I-b) (I-c) or its salt or its salt [wherein, R 1 , n and L are each as defined above.] In process 4, the compound (I-c) or its salt can be prepared by subjecting a compound (I-b) or its salt to reduction. The reduction is carried out by chemical reduction, catalytic reduction, or the like. Suitable reducing agents to be used in chemical reduction are a combination of metal [e.g. tin, zinc, iron, etc.] or metallic compound [e.g. chromium chloride, chromium acetate, etc.] and an organic or inorganic acid [e.g. formic acid, acetic acid, propionic acid, trifluoroacetic acid, p-toluenesulfonic acid, hydrochloric acid, hydrobromic acid, etc.]. Suitable catalysts to be used in catalytic reduction are conventional ones such as platinum catalyst [e.g. platinum, platinum black, platinum oxide, etc.], palladium catalyst [e.g. palladium black, palladium oxide, palladium on carbon, etc.], nickel catalyst [e.g. reduced nickel, nickel oxide, Raney nickel, etc.], or the like. The reduction is usually carried out in a conventional solvent which does not adversely influence the reaction such as water, an alcohol [e.g. methanol, ethanol, propanol, etc.], N,N-dimethylformamide, or a mixture thereof. Additionally, in case that the above-mentioned acids to be used in chemical reduction are in liquid, they can also be used as a solvent. The reaction temperature of this reduction is not critical and the reaction is usually carried out under cooling to warming. The compound of the present invention can be purified by any conventional purification methods employed for purifying organic compounds, such as recrystallization, column chromatography, thin-layer chromatography, high-performance liquid chromatography and the like. The compounds can be identified by conventional methods such as NMR spectrography, mass spectrography, IR spectrography, elemental analysis, and measurement of melting point. Some of the starting compounds (II) or (111) are novel and can be prepared by the well-known processes or its analogous processes, for example, the processes described in the J. Med. Chem. 1998, 41, 5247-5256 and J. Org. Chem., 21, 478- (1956). The following processes are given as an example. Reference Process 1 Reference Process 2 or its reactive derivative or its reactive derivative at the amino group, at the carboxy group, or its salt or its salt 1 1 [wherein, R , R , n, L and L are each as defined above.] Suitable salts of the compounds of the present invention are pharmaceutically acceptable conventional non-toxic salts and can be an organic acid addition salt (e.g. formate, acetate, trifluoroacetate, maleate, tartarate, oxalate, methanesulfonate, benzenesulfonate, toluenesulfonate, etc.), an inorganic acid addition salt (e.g. hydrochloride, hydrobromide, sulfate, phosphate, etc.), a salt with an amino acid (e.g. aspartic acid salt, glutamic acid salt, etc.), or the like. The "prodrug" means the derivatives of compounds of the present invention having a chemically or metabolically degradable group, which becomes pharmaceutically active after biotransformation. The compounds of formula (I) may contain one or more asymmetric centers and thus they can exist as enantiomers or diastereoisomers. Furthermore certain compounds of formula (I) which contain alkenyl groups may exist as cis- or trans-isomers. In each instance, the invention includes both mixtures and separate individual isomers. The compounds of the formula (I) may also exist in tautomeric forms and the invention includes both mixtures and separate individual tautomers. The compound of the formula (I) and its salt can be in a form of a solvate, which is included within the scope of the present invention. The solvate preferably include a hydrate and an ethanolate. Also included in the scope of invention are radiolabelled derivatives of compounds of formula (I) which are suitable for biological studies. In the above and subsequent description of the present specification, suitable examples and illustrations of the various definitions, which the present invention includes within the scope thereof, are explained in detail as follows. - The term "lower" means a group having 1 to 6 carbon atom(s), unless otherwise provided. Suitable "lower alkyl" and lower alkyl moiety in the terms "hydroxy(lower)alkyl", "lower alkylsulfonyl", "lower alkylthio" and "heteroaryl(lower)alkyl" include a straight or branched alkyl having 1 to 6, in particular 1 to 2, carbon atoms. Preferable examples which may be mentioned are methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl and hexyl. Preferable example which may be mentioned as "hydroxy(lower)alkyl" is hydroxy methyl. Preferable examples which may be mentioned as "lower alkylsulfonyl" are methylsulfonyl and ethylsulfonyl. Preferable examples which may be mentioned as "lower alkylthio" are methylthio and ethylthio. Suitable "lower alkenyl" includes a straight or branched alkenyl having 2 to 6 carbon atoms. Preferable xamples which may be mentioned are ethenyl(vinyl), propenyl (i.e., allyl or 1 -propenyl), butenyl and isobutenyl. Suitable "lower alkynyl" and lower alkynyl moiety in the term "aryl(lower)alkynyl" include a straight or branch alkynyl having 2 to 6 carbon atoms. Preferable examples which may be mentioned are ethynyl and propynyl. Preferable example which may be mentioned as "aryl(lower)alkynyl" is phenyl ethynyl. Suitable "lower alkylene" includes a straight or branched alkylene having 1 to 6, in particular 3, carbon atoms. Preferable examples which may be mentioned are methylene, ethylene, trimethylene, propylene, methyltrimethylene (1- or 2- methyltrimethylene) and hexamethylene, preferably trimethylene. Suitable "lower alkenylene" includes a straight or branched alkenylene having 1 to 6, in particular 3, carbon atoms. Preferable examples which may be mentioned are vinylene, propenylene, dimethylpropenylene (e.g., 3.3-dimethylpropenylene, etc.) and hexenylene preferably propenylene. Suitable "lower alkoxy" and lower alkoxy moiety in the term "aryl(lower)alkoxycarbonyl" includes straight or branched alkoxy having 1 to 6, in particular 1 to 2, carbon atoms. Preferable examples which may be mentioned are methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, iso-butoxy, sec-butoxy and tert-butoxy, preferably methoxy. Suitable "lower alkylamino" and lower alkylamino moiety in the term "aryl(lower)alkylamino" include mono(lower)alkylamino and di(lower)alkylamino. Preferable examples which may be mentioned are methylamino, dimethylamino, ethylamino, dimethylamino, n-propylamino, isopropylamino, n-butylamino, iso-butylamino, sec-butylamino and tert-butylamino, preferably dimethylamino and diethylamino. Suitable "aryl" and aryl moiety in the terms "aryloxy", "aryl(lower)alkynyl", "aryl(lower)alkylamino" and "aryl(lower)alkoxycarbonyl" may be intended to mean a mono-, di- or polynuclear aromatic radical having preferably 6 to 12 carbon atoms, such as phenyl, naphthyl, tetrahydronaphthyl, indenyl, indanyl (1,2-dihydroindenyl), fluorenyl and the like, preferably phenyl or naphthyl. Preferable examples which may be mentioned as "aryloxy" are phenoxy and naphtyloxy. Preferable example which may be mentioned as "aryl(lower)alkoxycarbonyl" is benzyloxycarbonyl. Suitable "aryl(lower)alkyl" and aryl(lower)alkyl moiety in the term "aryl(lower)alkylamino" means arylalkyl which has preferably 6 or 10 carbon atoms in the aryl part (preferably phenyl or naphthyl, in particular phenyl) and preferably 1 to 6, in particular 1 to 4, carbon atoms in the alkyl part, it being possible for the alkyl part to be straight-chain or branched. Benzyl, 2-phenylethyl, 3-phenylpropyl, 4-phenylbutyl and naphtylmethyl may be mentioned as examples and as preferred. Preferable examples which mentioned as "aryl(lower)alkylamino" are benzylamino and phenetylamino. Suitable "acyl" and acyl moiety in the "acylamino" may be aliphatic acyl, aromatic acyl, aliphatic acyl optionally substituted aryl or heteroaromatic acyl, which are derived from carboxylic acid. The aliphatic acyl may include (1) lower alkanoyl optionally substituted with one or more suitable substituent(s) such as hydroxy, lower alkoxy, carboxy, protected carboxy, halogen, lower alkylthio, heterocyclicthio, oxo, cyclo(lower)alkyl or a heterocyclic group (e.g. formyl, acetyl, propionyl, butyryl, isobutyryl, pentanoyl, hexanoyl, 3,3-dimethylbutanoyl, 3 -hydroxy-3 -methylbutanoyl, 3 -oxo-butanoyl, 3 -methoxycarbonylpropanoyl, 3-carboxypropanoyl, 4-methoxycarbonylbutanoyl, 4-carboxybutanoyl, methylthioacetyl, (l-methylimidazol-2-yl)thioacetyl, hydroxyacetyl, methoxyacetyl, ethoxyacetyl, 3-methoxybutanoyl, chloroacetyl, morpholinoacetyl, piperidinylacetyl, 4-methylpiperidin- 1 -ylacetyl, 4-hydroxypiperidinyl, pyrolidinylacetyl, 4-(pyrimidin-2-yl)piperidinylacetyl, 3-hydroxypyrrolidinylacetyl, oxolan-4-ylacetyl, and so on); (2) cyclo(lower)alkanecarbonyl (e.g. cyclopropylcarbonyl, cyclobutylcarbonyl, cyclopentylcarbonyl, cyclohexylcarbonyl, and so on); (3) lower alkenoyl (e.g. acryloyl, methacryloyl, crotonoyl, 3 -methylbutanoyl, and so on); The aromatic acyl may include aroyl optionally substituted with one or more suitable substituent(s) such as nitro (e.g. benzoyl, naphthoyl, nitrobenzoyl, and so on), or the like. The aliphatic acyl substituted with aryl may include ar(lower)alkanoyl which may have one or more suitable substituent(s) such as lower alkoxy (e.g. phenylacetyl, 4-methoxyphenylacetyl, and so on) or the like. The heteroaromatic acyl is a carbonyl group to which is binded to heteroaryl, such as furylcarbonyl or the like. The term "halogen" means fluoro, chloro, bromo or iodo. Suitable "halo(lower)alkyl" and halo(lower)alkyl moiety in the term "halo(lower)alkoxy" contains 1 to 4, in particular 1 or 2, carbon atoms, and preferably 1 to 9, in particular 1 to 5, identical or different halogen atoms, preferably fluorine, chlorine and bromine, in particular fluorine and chlorine. Examples which may be mentioned are trifluoromethyl, trichloromethyl, chlorodifluoromethyl, dichlorofluoromethyl, chloromethyl, bromomethyl, 1-fluoroethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 2,2,2-trichloroethyl and pentafluoroethyl, preferably trifluoromethyl. Suitable "heteroaryl" and heteroaryl moiety in the terms "heteroaryl(lower)alkyl" and "heteroaromatic acyl" is intended to mean 5- to 7-membered rings having preferably 1 to 3, in particular 1 or 2, identical or different heteroatoms. Heteroatoms in the heteroaryl are oxygen, sulfur or nitrogen. Examples which may be mentioned are furyl, thienyl, pyrazolyl, imidazolyl, triazolyl (e.g., 1,2,3- and 1,2,4-triazolyl, etc.), isoxazolyl, thiazolyl, isothiazolyl, oxadiazolyl (e.g., 1,3,4-, and 1,2,5-oxadiazolyl, etc.), azepinyl, pyrrόlyl, pyridinyl, piperazinyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl (e.g., 1,3,5-, 1,2,4- and 1,2, 3 -triazinyl, etc.), oxazinyl (e.g., 1,2,4- and 1,2,6-oxazinyl, etc.), oxepinyl, thiepinyl and diazepinyl (e.g., 1,2,4-diazepinyl, etc.), preferably thienyl, pyrazolyl, imidazolyl, thiazolyl, pyridinyl and pyrazinyl. Suitable "cyclic amino group" are heteroaromatic or aliphatic ring systems having one or more nitrogen atoms as the heteroatom, in which the heterocyclic rings can be saturated or unsaturated, can be one ring system or several fused ring systems, and optionally contain further heteroatoms, suchas nitrogen, oxygen and sulfur and the like. Cyclic amino groups can furthermore also denote a spiro ring or a bridged ring system. The number of atoms which form cyclic amino groups is not limited, for example in the case of a single-ring system, they comprise 3 to 8 atoms, and in the case of a three-ring system, they comprise 7 to 11 atoms. Preferable examples of "cyclic amino group" are described as follows: (1) examples which may be mentioned of cyclic amino group with saturated monocyclic groups with one or more nitrogen atom(s) as the heteroatom are azetidinyl (3-azetidinyl), pyrrolidinyl (e.g., 1- and 3-pyrrolidinyl, etc.), piperidyl (e.g., 1- and 4-piperidyl, etc.), homopiperidino (e.g., hexahydro-lH-azepin-1-yl, etc.), homopiperazinyl (e.g., hexahydro-lH-l,4-diazepin-l-yl, etc.), imidazolidinyl (e.g., 1-imidazolidinyl, etc.), piperazinyl (e.g., 1 -piperazinyl, etc.), perhydropyrimidinyl (e.g., perhydropyrimidin-1-yl, etc.) and diazacycloheptanyl (e.g., 1,4-diazacycloheptan-l-yl, etc.); (2) examples which may be mentioned of cyclic amino group with unsaturated monocyclic groups with one or more nitrogen atom(s) as the heteroatom are pyrrolinyl (e.g., 2-pyrrolin-l-yl, etc.), pyrrolyl (e.g, 1-pyrrolyl, etc), tetrahydropridinyl (e.g., 3,6-dihydro-l(2H)-pyridinyl, etc.), pyridinyl (e.g., 2-pyridinyl, etc.), tetrahydroazepinyl (e.g., 2,3,6,7-tetrahydro-lH-azepin-l-yl, 2,3,4,7-tetrahydro-lH-azepin-l-yl, etc.), imidazolyl (1 -imidazolyl), pyrazolyl, triazolyl, tetrazolyl, tetrazolyl, pyrimidinyl, pyrazinyl, pyridazinyl, dihydro-pyridazinyl (e.g., 1,2-dihydro-pyridazin-l-yl, etc.) and dihydro-pyrimidinyl (e.g., 1,2-dihydro-pyrimidin-l-yl, etc.); (3) examples which may be mentioned of cyclic amino groups with saturated and unsaturated monocyclic groups with one to three nitrogen atoms and one to two sulfur atoms as heteroatoms are thiazolidinyl (e.g., 3-thiazolidinyl, etc.), isothiazolinyl (e.g., 2-isothiazolinyl, etc.) and thiomorpholino; (4) examples which may be mentioned of cyclic amino groups with saturated and unsaturated monocyclic groups with one to three nitrogen atoms and one to two oxygen atoms as heteroatoms are oxazolyl, isoxazolyl, oxadiazolyl (e.g., 1,2,4-oxadiazolyl, and 1,3,4-oxadiazolyl) or morpholinyl; (5) examples which may be mentioned of cyclic amino groups with saturated and unsaturated fused cyclic groups are indolyl (e.g., 1-indolyl, etc.), dihydrobenzimidazolyl (e.g., 1,2-dihydrobenzimidazol-l-yl, etc.), perhydropyrrolo[l,2-a]pyrazinyl (e.g., perhydropyrrolo[l,2-a]pyrazin-2-yl, etc.), tetrahydrobenzo[f]isoquinolinyl (e.g., l,4,5,6-tetrahydrobenzo[f|isoquinolin-3(2H)-yl, etc.), hexahydrobenz[f isoquinolinyl (e.g., cis- and trans-l,4,4a,5,6,10b-hexahydrobenz[f]isoquinolin-3(2H)-yl, etc.), tetrahydropyrido[3,4-b]indolyl (e.g., l,3,4,9-tetrahydro-2H-ρyrido[3,4-b]indol-2-yl, etc.) tetrahydrobenzazepinyl (e.g., l,2,4,5-tetrahydro-3H-3-benzazepin-3-yl, etc.) dihydroisoquinolinyl (e.g., 3,4-dihydro-2(lH)-isoquinolinyl, etc.); (6) examples which may be mentioned of cyclic amino groups with spirocyclic groups are azaspiro[4,5]decanyl (e.g., 2-azaspiro[4,5]decan-2-yl, etc.), spiro[lH-indene-l,4'-piperidinyl] (e.g., spiro[lH-indene-l,4'-piperidin- -yl], etc.), and dihydrospiro[lH-indene-l,4'-piperidinyl] (e.g., 2,3-dihydrospiro[lH-indene-l,4'-piperidin-r-yl], etc.); (7) examples which may be mentioned of cyclic amino groups bridged heterocyclic groups are azabicyclo[2,2,l]heptanyl (e.g., 2-azabicyclo[2,2,l]heptan-7-yl, etc.) and diazabicyclo[2.2.1]heptyl (e.g., 2,5-diazabicyclo[2.2.1]hept-2-yl, etc.). Among the above, preferable "cyclic smino group" included in Rl is above-mentioned (1) or (2), in which the most preferable one is piperidinyl, tetrahydropyridinyl and piperazinyl. It has been known that, during major cellular stresses, the activation of PARP can rapidly lead to cell damage or death through depletion of energy stores and PARP activation play a key role in both NMD A- and NO-induced neurotoxicity (Zhang et. al., Science, 263: 687-89 (1994)). Therefore, the compound possessing PARP inhibiting activity, such as the compound (I) of this invention, or pharmaceutically acceptable salts are useful in treating and preventing various diseases ascribed by NMD A- and NO-induced toxicity. Such diseases include, for example, tissue damage resulting from cell damage or death due to necrosis or apoptosis; neural tissue damage resulting from ischemia and reperfusion injury, neurological disorders and neurodegenerative diseases; neurodegenerative diseases; head trauma; stroke; Alzheimer's disease; Perkinson's disease; epilepsy; amyotrophic lateral scleosis (ALS); Huntington's disease; schizophrenia; chronic pain; ischemia and neuronal loss following hypoxia; hypoglycemia; ischemia; trauma; and nervous insult. It has been demonstrated that PARP inhibitor are useful in deducing infarct size (Thiemermann et al, Proc. Natl. Acad. Sci. USA, 94: 679-83 (1997)). Therefore, the compound possessing PARP inhibiting activity, such as the compound (I) of this invention, or pharmaceutically acceptable salts are useful in treatment and prevention of previously ischemic heart or skeleton muscle tissue. It is also known that PARP is thought to play a role in enhancing DNA repair. So, the compound possessing PARP inhibiting activity, such as the compound (I) of this invention, or pharmaceutically acceptable salts are effective in treating and preventing radiosensitizing hypoxic tumor cells; tumor cells from recovering from potentially lethal damage of DNA after radiation therapy. Further, the compound possessing PARP inhibiting activity, such as the compound (I) of this invention, or pharmaceutically acceptable salts are useful in extending the life-span and proliferative capacity of cells and altering gene expression of senescent cells. They are useful for treating and preventing skin aging; Alzheimer's diseases; atheroscleosis; osteoarthritis; osteoporosis; muscular dystrophy; degenerative diseases of skeletal muscle involving replicative senescence; age-related macular degeneration; immune senescence; AIDS; and other immune senescence diseases. Still further, the compound possessing PARP inhibiting activity such as the compound (I) of this invention, or pharmaceutically acceptable salts are effective in treating and preventing inflammatory bowel disorders (e.g., colitis); arthritis; diabetes; endotoxic shock; septic shock; and tumor. Also, they are useful in reducing proliferation of tumor cells and making synergistic effect when tumor cells are co-treated with an alkylating drug. The compound possessing PARP inhibiting activity, such as the compound (I) of this invention, or pharmaceutically acceptable salts are effective in treating and preventing pituitary apoplexy; conjunctivitis; retinoblastoma; retinopathy; acute retinal necrosis syndrome; Sjogren's syndrome. The compound (I), its prodrug, or their salt can be administered alone or in the form of a mixture, preferably, with a pharmaceutical vehicle or carrier. The active ingredient of this invention can be used in the form of a pharmaceutical preparation, for example, in solid, semisolid or liquid form, which contains a compound (I), as an active ingredient, in admixture with an organic or inorganic carrier or excipient suitable for external (topical), enteral, intravenous, intramuscular, parenteral or intramucous applications. The active ingredient can be formulated, for example, with the conventional non-toxic, pharmaceutically acceptable carriers for ointment, cream, plaster, tablets, pellets, capsules, suppositories, solution (saline, for example), emulsion, suspension (olive oil, for example), aerosols, pills, powders, syrups, injections, troches, cataplasms, aromatic waters, lotions, buccal tablets, sublingual tablets, nasal drops and any other form suitable for use. The carriers which can be used are water, wax, glucose, lactose, gum acacia, gelatin, mannitol, starch paster, magnesium trisilicate, talc, corn starch, keratin, paraffin, colloidal silica, potato starch, urea and other carriers suitable for use in manufacturing preparations, in solid, semisolid, or liquid form, and in addition auxiliary, stabilizing, thickening and coloring agents and perfumes may be used. The active compound is included in a pharmaceutical composition in an effective amount sufficient to produce the desired effect upon the process or condition of the diseases. The active ingredient can be formulated into, for example, preparations for oral application, preparations for injection, preparations for external application, preparations for inhalation, preparations for application to mucous membranes. Mammals which may be treated by the present invention include livestock mammals such as cows, horses, etc., domestic animals such as dogs, cats, rats, etc. and humans, preferably humans. While the dosage of therapeutically effective amount of the compound (I) will vary depending upon the age and condition of each individual patient, an average single dose to a human patient of about 0.01 mg, 0.1 mg, 1 mg, 10 mg, 50 mg, 100 mg, 250 mg, 500 mg, and 1000 mg of the compound (I) may be effective for treating the above-mentioned diseases. In general, amounts between 0.01 mg/body and about 1,000 mg/body may be administered per day. In order to illustrate the usefulness of the object compound (I), the pharmacological test data of the compound (I) are shown in the following. A. Test Compound 5-chloro-2-[3-(4-phenyl-3, 6-dihydro- 1 (2H)-pyridinyl)propyl]-4(3H)-quinazolinone (Compound A: The compound of Example 1) 8-chloro-2- { ( 1 E)-3 -[4-(4-fluorophenyl)-3 , 6-dihydro- 1 (2H)-pyridinyl] - 1 -propenyl } - 4(3H)-quinazolinone (Compound B: The compound of Example 33 (1)) 8-Chloro-2-{[4-(4-pyridinyl)-3,6-dihydro-l(2H)-pyridinyl] propyl}- 4(3H)-quinazolinone (Compound C: The compound of Example 35 (15)) 8-methyl-2-[3-(l,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)ρropyl]- 4(3H)-quinazolinone (Compound D: The compound of Example 38 (2)) B. PARP inhibitory activity (In vitro assay) (1) Assay conditions: The recombinant human PARP (5.3mg protein/ml) were incubated with a test compound in a lOOμl reaction buffer containing the indicated concentration of 1 mCi/ml 32 P-NAD, 50mM Tris-HCl, 25mM MgCl 2 , lmM DTT (dithiothreitol), 0.05mMNAD (nicotinamido adenine dinucleotide), lmg/ml activated DN pH8.0. Incubation was for 15 minutes at a room temperature and the reaction was stopped by the addition of 200μl of ice-cold 20% tricholoroacetic acid followed by rapid filtration through GF/B filters. The filters were treated with scintillation fluid and acid-insoluble counts were measured for quantification of unit activity. PARP inhibitory activity (%) = [1 -(enzyme activity with test compound)/(enzyme activity with vehicle)] xlOO (2) Result PARP inhibitory activity (IC 50 ) in test compound. C. Effect of test compound on the level of striatal dopamine and its metabolite in mice MPTP(N-methyl- 1,2, 3, 6-tetrahydropyridine)-induced Parkinson's model (1) Method Mice received four i.p. injections of MPTP-HC1 (20mg/kg) in saline at 2hours intervals and two i.p. injections of Test compound at 30minutes before 1st injection and 3rd injection of MPTP. Four days after the last MPTP injection, mice were sacrificed, brains were quickly removed, and striata were dissected out on an ice-cold glass Petri dish. Samples were homogenized in a buffer of 0.1M perchloric acid containing isoproterenol as internal standard. HPLC with electrochemical detection was used to measure striatal levels of of DA (dopamine), DOPAC (dihydroxyphenylacetic acid) and HVA (homovanilic acid). (2) Results The level of DA, DOPAC and HVA were expressed as a percentage of Normal taken as the 100%. * P<0.05 vs MPTP (by Student's t-test) This invention relates to novel Quinazoline compounds had a potent PARP inhibitory activity. PARP inhibitors including this invention relates to novel quinazoline compounds were effective in preventing reduction of striatal DA and its metabolite induced by MPTP treatment in mice. Therefore, it suggests that these compounds may have protective benefit in the treatment of neurodegenerative disease such as Parkinson's disease. Abbreviations used herein have the following meanings: ABBREVIATION DEFINITION Me methyl Et ethyl tBu tert-buthyl Bzl benzyl Ph phenyl Ac acetyl Bz benzoyl Any patents, patent applications, and publications cited herein are incorporated by reference. Best Mode for Carrying out the Invention The following Preparation and Examples are given for the purpose of illustrating the present invention in detail, but are not to be construed to limit the scope of the present invention. Preparation 1 2-Amino-6-chlorobenzoic acid (150g, 874mmol) was added slowly to thionyl chloride (383 mL, 5.25mol) at 5 °C and the mixture was refluxed for 2 hours. Thionyl chloride was removed in vacuo. Toluene was added and removed in vacuo. The obtained acid chloride was dissolved in dioxane (750 mL). The solution was added dropwise to NH4OH (27%, 835mL, 4.37mol) at 5 °C. The mixture was concentrated in vacuo. The reaction mixture was extracted with ethyl acetate. Hexane was added to the organic layer, and the precipitate was corrected with filtration. The resulting crystals were dried to give 2-amino-6-chlorobenzamide (95.8g, 577mmol, 64%). 1H MR (300MHz, CDC1 3 , δ): 4.84 (2H, br.s), 5.97QH, br.s), 6.20QH, br.s), 6.60QH, d, J=8.2 Hz), 6.73 (1H, d, J=8.0 Hz), and 7.07 (1H, t, J=8.1 Hz) Mass (m/z): 171 (M^+l) Preparation 2 To a mixture of 2-amino-6-chlorobenzamide (lOOg, 586mmol) and diisopropyl-ethylamine (123 mL, 703mmol) in THF (IL) 4-pentenoyl chloride (74.4mL, 674mmol) was added dropwise at 5 °C. The mixture was stirred for 30 minutes. Saturated sodium hydrogen carbonate aqueous solution was added and the precipitate was corrected by filtration and washed with water to give 2-chloro-6-(4-pentenoylamino)benzamide, which was used without further purification. 1H MR (300MHz, CDC1 3 , δ): 2.47(4H, s), 5.03 (1H, dd, J=10. ιHz, <lHz), 5.13 (1H, dt, J=7.9Hz, <lHz), 5.85 (1H, m), 6.15QH, br.s), 6.28(1H, br.s), 7.34 (1H, t, J=8.3 Hz), 7.16 (1H, d, J=9.1 Hz, 8.23 (1H, d, J=8.4 Hz), and 9.26 (1H, br.s). Mass (m/z): 253 (M + +l) Preparation 3 2-Chloro-6-(4-pentenoylamino)benzamide (148g, 586mmol) was dissolved in dioxane (IL), and IN NaOH aqueous solution (1.17L) was added. The reaction mixture was stirred at room temperature for 2.5 hours. The reaction mixture was concentrated in vacuo, then the resulting solution was neutralized with IN HC1 aqueous solution. The precipitate was corrected with filtration and washed with ether to give 2-(3-butenyl)-5-chloro-4(3H)-quinazolinone (96.6g, 0.41mmol, 70% for two steps) as colorless crystals. 1H NMR (300MHz, CDC1 3 , δ): 2.66 (2H, q, J-7.3 Hz), 2.87 (2H, t, J=7.6 Hz), 5.05 (1H, d, J=9.9 Hz), 5.15 (1H, d, J=17.3Hz), 5.09 (1H, m), 7.45 (1H, m), and 7.66 (2H, m). Mass (m/z): 235 (M^+l) Preparation 4 OsO 4 (2.5% t-BuOH solution, 23.8mL, 2.34mmol) was added to 10% aqueous dioxane solution of 2-(3-butenyl)-5-chloro-4(3H)-quinazolinone (55g, 234mmol). After stirring for 10 minutes, NaIO 4 (HOg, 516mmol) was added to the mixture. The mixture was stirred at room temperature for 4 hours. The reaction mixture was extracted with AcOEt, and washed with 10% NaS 2 O 3 and brine. The organic layer was dried over MgSO 4 and the solvent was removed in vacuo. The residual yellow solid was purified by silica gel chromatography eluting with chloroform and methanol (100: 1-100:2) to give 8-chloro-l-hydroxy-2,3-dihydropyrrolo[2,l-b]quinazoline-9(lH)-one (26.5g, HOmmol, 48%o) was obtained as colorless powder. 1H NMR (300MHz, CDC1 3 , δ): 2.22 (1H, m), 2.50 (1H, m), 3.04 (1H, m), 3.35 (1H, m), 4.36 (1H, br.s), 6.28 (1H, m), 7.46 (1H, m), and 7.59 (2H, m). Mass (m/z): 237 (M + +l) Preparation 5 Benzylchloride (3.25mL, 28.2mmmol) was added to the mixture of 4-phenyl-4-hydroxypiperidine and t-BuOK (3.17g, 28.2mmol) in t-butanol (70mL), and the mixture was refluxed for 2 hours. Methanol (30mL) was added to the mixture and inorganic solid was filtered off. The solution was concentrated in vacuo and extracted with AcOEt, washed with brine. Solvent was removed in vacuo, and the residual solid was washed with diisopropylether/hexane (1 : 10) to give . l-benzyl-4-hydroxy-4-phenylpiperidine (6.32g, 23.6mmol, 84%) as colorless powder. 1H NMR (300MHz, CDC1 3 , δ): 1.74(2H, dm, J=14.1Hz), 2.18 (2H, td, J=13.0 Hz, 4.4 Hz), 2.48 (2H, tm, J=13.0 Hz), 2.80 (2H, dm, J=ll.l Hz), 3,59 (2H, s), 7.23-7.30 (3H, m), 7.33-7.38 (5H, m), and 7.52 (2H, dm, J=7.9 Hz). Mass (m/z): 268 (M + +l). Preparation 6 Sulfuric acid (16.7mL, 314mmol) was added dropwise to dispersion of l-benzyl-4-hydroxy-4-phenylpiperidine (6g, 22.4mmoi) in acetonitrile (25.8mL, 494mmol) at 0 °C, and the mixture was stirred at room temperature for 30 minutes. The reaction mixture was poured into cold water. The solution was adjusted to pH 9 with saturated sodium hydrogen carbonate aqueous solution and IN NaOH aqueous solution. The mixture was extracted with AcOEt, washed with saturated sodium hydrogen carbonate aqueous solution and brine. Solvent was removed in vacuo. Residual colorless solid was washed with ether to give 4-acetoamide-l-benzyl-4-phenylpiperidine (5.8g, 19.0mmol, 84%) as colorless powder. 1H NMR (300MHz, CDC1 3 , δ): 2.03 (3H, m), 2.12 (2H, m), 2.30 (4H, m), 2.80 (2H, d, J=12.2 Hz), 3.53 (2H, s), 5.53 (1H, br.s), and 7.4-7.18 (10H, m). Mass (m z): 309 (M + +l) Preparation 7 4-Acetoamide-l-benzyl-4-phenylpiperidine (2.7g, 8.75mmol) was dissolved in 6N aqueous HC1 (7.27mL, 43.8mmol) at 130 °C. After the solution was cooled to room temperature, IN NaOH aqueous solution was added. The reaction mixture was extracted with AcOEt, washed with saturated sodium hydrogen carbonate aqueous solution. The organic layer was dried over MgSO 4 and the solvent was removed in vacuo. The residual pale yellow oil was purified by silica gel chromatography eluting with chloroform and methanol (100:5-100:20) to give 4-amino-l -benzyl -4-phenylpiperidine (1.7g, 6.38mmol, 73%) as pale yellow oil. 1H NMR (300MHz, CDC1 3 , δ): 1J0(2H, m), 2.20 (2H, m), 2.50 (2H, m), 2.71 (2H, m), 3.57 (2H, s), 7.25 (2H, m), 7.35 (6H, tm, J=7.6 Hz), and 7.52 (2H, dm, J=7.24 Hz). Mass (m/z): 267 (MM) Preparation 8 4-Amino-l-benzyl-4-phenylpiperidine (500mg, 1.88mmol) and HCO NIΪ 4 (1.18g, 18.8mmol), and Pd-C (10%, 500mg) were disperted in ethanol/ffiO (lOmL/lOmL). The mixture was refluxed for 4 hours. Insoluble products were filtrated off, and the solvent was removed in vacuo. The residue was purified by reverse phase chromatography eluting by water to give 4-amino-4-phenylpiperidine (20mg, 11.3mmol, 13.7%) as colorless solid. 1H NMR (300MHz, CDC1 3 , δ): 1.73 (2H, m), 2J6 (2H, m), 2J9 (2H, m), 3.02 (2H, m), 7.22 (1H, tm, j=7.3 Hz), 7.35 (2H, tm, j=8.0 Hz), and 7.51 (2H, tm, J=7.3 Hz). Mass (m z): 177 (M + +1) Preparation 9 Oxalyl chloride was added to a solution of 4-(l-phenyl-4-piperidyl)-butanoic acid (200 mg, 0.809 mmol) in DMF (5 mL) under ice water bath, then the mixture was stirred for 1 hour. To a solution of 2-carbamoylaniline (110 mg, 0.809 mmol) in DMF (5 mL) was added N-ethyldiisopropylamine (0J69 mL, 0.97 mmol) under ice water bath, then the previous soluiton was added dropwise. After stirring 2hours at room temperature, the mixture was poured into ice water, extracted ethyl acetate twice, washed with saturated aqueous NaHCO 3 and brine, and dried over sodium sulfate. Evaporation of the solvent gave the residue, and purified by silica gel chromatography eluting with chloroform and methanol (20: 1) to give 2-[4-(l-phenyl-4-piperidyl)-butanoylamino]benzamide (100 mg, 0.26 mmol, 34%) as a pale yellow powder. 1H NMR (300MHz, CDC1 3 , δ): 1.26-1.50 ( 5H, m), 1.72-1.89 ( 4H, m), 2.42 ( 2H, t, J=7.5 Hz), 2.68 ( 2H, t, J=7.0 Hz), 3.66 ( 2H, d, J=7.0 Hz), 6.81 ( 1H, t, J=7.8 Hz), 6.94 ( 2H, d, J=7.8 Hz), 7.08 ( 1H, t, J=7.8 Hz), 7.24 ( 2H, d, J=7.8 Hz), 7.42-7.56 ( 2H, m), 8.67 ( 1H, d, J=7.8 Hz), 11.15 ( 1H, s) Mass (m/z): 366 (M 4 ) Preparation 10-(1) Under a nitrogen atmosphere, a solution of butyllithium (1.6 M in hexane, 10.8 mL) was added dropwise to a solution of l-bromo-4-methoxybenzene (3.04 g, 16.3 mmol) in tetrahydrofuran (30 mL) at -78 °C. The mixture was stirred at the temperature for 30 minutes, and a solution of tert-butyl 4-oxo-l-piperidinecarboxylate (2.7 g, 13.6 mmol) in tetrahydrofuran (20 mL) was added dropwise. The mixture was allowed to warm to -20 °C with stirring for 2 hours. The reaction was quenched by addition of saturated aqueous ammonium chloride, and the organic materials were extracted with ethyl acetate. The organic layer was washed with water and brine and dried over magnesium sulfate. Purification over silica gel chromatography gave tert-butyl 4-hydroxy-4-(4-methoxyphenyl)-l-piperidinecarboxylate (3.04 g, 73.0 %) as oil. 1H NMR (200MHz, CDC1 3 , δ): 1.48 (9H, s), 1.73 (2H, br d, J=12.0 Hz), 1.97 (2H, dt, J=12.5, 2.4 Hz), 3.24 (2H, br t, J=11.6 Hz), 3.81 (3H, s), 4.02 (2H, br d, J=9.8 Hz), 6.89 (2H, d, J=8.9 Hz), 7.39 (2H, d, J=8.9 Hz) Mass (APCI+, 50V): 330.3 (M + +Na) Preparation 10-(2) Trifluoroacetic acid (7.6 mL, 98.9 mmol) was added to an ice-cooled solution of tert-butyl 4-hydroxy-4-(4-methoxyphenyl)-l-piperidinecarboxylate (3.04 g, 9.89 mmol) in dichloro methane (15 mL), and the mixture was stirred at 0 °C for 1 hour. Trifluoroacetic acid and dichloromethane were removed in vacuo, and the crude product was treated with ethyl acetate and aqueous sodium hydrogen carbonate. The organic layer was separated, and dried over sodium sulfate. The evaporated residue was treated with a solution of hydrogen chloride (4 M in ethyl acetate, 5 mL) in ice-cooled ethyl acetate (15 mL) for 1 hour to give 4-(4-methoxyphenyl)-l,2,3,6-tetrahydropyridine hydrochloride (1.63 g, 73.0 %) as powder. 1H NMR (200MHz, DMSO-d 6 , δ): 2.66 (2H, br), 3.27 (2H, br), 3.70 (2H, br), 3.76 (3H, s), 6.08 (1H, m), 6.94 (2H, d, J=8.8 Hz), 7.42 (2H, d, J=8.8 Hz), 9.29 (2H, br) Mass (API-ES+): 190.4 (M + +H) Preparation 11 Tert-butyl 4-hydroxy-4-[4-(trifluoromethyl)phenyl]- 1 -piperidinecarboxylate was prepared in a similar procedure to that of Preparation 10-(1), which was used for the next step (Preparation 12). Preparation 12 Methanesulfonyl chloride (3.44 mL, 44.4 mmol) was added dropwise to a solution of tert-butyl 4-hydroxy-4-[4-(trifluoromethyl)phenyl]- 1 -piperidinecarboxylate (includes tert-butyl 4-oxo-l -piperidinecarboxylate, 5.H g) in triethylamine (20.6 mL) and dichloromethane (60 mL) at -78 °C. 4-Dimethylaminopyridine (90 mg, 0.74 mmol) was added, and the mixture was allowed to warm to 0 °C and was stirred for 2 hours at 0 °C. Quenched with water, and the organic materials were extracted with chloroform. Solvents were removed in vacuo, and the residue was dissolved in dichloromethane (50 mL) and triethylamine (20 mL), and stirred for 2 days at room temperature. Quenched by the addition of water, and the product was extracted with CHC1 3 . Purification over silica gel (hexane: ethyl acetate=10:l) gave tert-butyl 3,6-tetrahydro-4-[4-(trifluoromethyl)phenyl]-l(2H)-pyridinecarboxylate (3.57 g, 73.7 %). 1H NMR (200MHz, CDC1 3 , δ): 1.50 (9H, s), 2.53 (2H, m), 3.65 (2H, t, J=5.7 Hz), 4.10 (2H, q, J=2.8 Hz), 6.12 (1H, br), 7.46 (2H, d, J=8.4 Hz), 7.58 (2H, d, J=8.5 Hz) Mass (API-ES): 350.3 (M÷+Na) Preparation 13 A solution of hydrogen chloride (4 M in ethyl acetate, 16.4 mL) was added to a solution of tert-butyl 3,6-tetrahydro-4-[4-(trifluoromethyl)phenyl]-l(2H)-pyridinecarboxylate (3.57 g, 10.9 mmol) in ethyl acetate (4 mL) at 0 °C. The mixture was stirred for 1.5 hr at the temperature. Evaporated to dryness, and the residue was washed with ethyl acetate and diisopropyl ether to give 4-[4-(trifluoromethyl)phenyl]-l,2,3,6-tetrahydropyridine hydrochloride (2.61 g, 90.8 %) as white powder. 1H NMR (200MHz, DMSO-d 6 , δ): 2.73 (2H, br), 3.32 (2H, t, J=6.0 Hz), 3.78 (2H, m), 6.37 (1H, br), 7.70 (2H, d, J=8.9 Hz), 7.76 (2H, d, J=9.0 Hz), 9.38 (2H, br s) Mass (API-ES): 228.3 (M + +H) Preparation 14 Under a nitrogen atmosphere, a mixture of tert-butyl 4-(((trifluoromethyl)sulfonyl)oxy)-3,6-dihydro-l(2H)-pyridinecarboxylate (1.0 g, 3.02 mmol), 4-cyanophenylboronic acid (532 mg, 3.62 mmol), triethylamine (1.26 mL, 9.05 mmol) and tetrakis(triphenylphosphine)palladium (35 mg, 0.030 mmol) in N,N-dimethylformamide (15 mL) was stirred for 2 hours at 100 °C. Quenched with water, and the product was extracted with ethyl acetate. Solvents were removed in vacuo 5 (treated with toluene once azeotropically) to give the crude product. It was treated with a solution of hydrogen chloride (4 M in ethyl acetate, 5 mL) in ice-cooled ethyl acetate (7 mL) for 1 hour. The precipitate was collected by filtration and washed with ethyl acetate and diisopropyl ether to give 4-(l,2,3,6-tetrahydro-4-pyridinyl)benzonitrile hydrochloride (460 mg, 54.5 %) as white powder. 10 1H NMR (200MHz, DMSO-d 6 , δ): 2.50 (2H, m), 2.70 (2H, br), 3.80 (2H, br), 6.42 (IH, m), 7.68 (2H, d, J=8.6 Hz), 7.86 (2H, d, J=8.6 Hz), 9.05 (2H, br) Preparation 15 A mixture of 2-amino-3-iodobenzoic acid (1.12 g) and thionyl chloride (3.11 ml) 15 was refluxed for 1 hour. The mixture was cooled, concentrated and co-evaporated with toluene twice. To 28% ammonia aqueous solution was added dropwise a solution of the residue in dichloromethane, then the resulting powder was collected, washed with water and dried in vacuo to give the 2-amino-3-iodobenzamide. 1H MR (DMSO-d 6 , δ): 6.37 (IH, t, J=7.8 Hz), 6.58 (2H, brs), 7.30 (IH, brs), 7.59 (IH, dd, 20 J=1.4 Hz,J=7.8 Hz), 7.90 (IH, brs). Mass (ESI): 285.1 (M'+Na) Preparation 16 The following compounds are prepared in a similar manner to that of Preparation 25 15. (1) 2-Amino-3-ethylbenzamide 1H NMR (DMSO-dg, δ): 1.13 (3H, t, J=7.4 Hz), 2.45 (2H, q, J=7.4 Hz), 6.20-6.70 (3H, m), 6.80-7.20 (2H, m), 7.42 (IH, dd, J=1.3, 7.9 Hz), 7.71 (IH, brs) Mass (ESI): 187.2 (M + +Na) 30 (2) 2-amino-3-bromobenzamide Mass (ESI): 239.1 (M'+Na) Preparation 17 Under a nitrogen atmosphere, a solution of 4-bromobutyryl chloride (4.9 g, 26.4 35 mmol) in dichloromethane (10 mL) was added dropwise to the solution of 2-aminobenzamide (3.0 g, 22 mmol) in pyridine (18 mL, 220 mmol) and dichloromethane (15 mL) at 0 °C. The mixture was stirred for 1.5 hours at 0 °C. The reaction mixture was poured into ice-cooled IN hydrochloric acid, and the product was extracted with chloroform. The organic layer was washed with IN hydrochloric acid and water and dried over sodium sulfate. The crude product was triturated with toluene to give 2-[(4-bromobutanoyl)amino]benzamide (5.H g, 81.3 %) as powder. 1H NMR (200MHz, CDC1 3 , δ): 2.29 (2H, quint., J=6.8 Hz), 2.61 (2H, t, J=7.2 Hz), 3.52 (2H, t, J=6.4 Hz), 5.5-6.5 (2H, br), 7.09 (IH, dt, J=7.6, IT Hz), 7.51 (IH, t, J=7.6 Hz), 7.53 (IH, d, J=7.6 Hz), 8.62 (IH, d, J=8.5 Hz), 11.25 (IH, s) Mass (API-ES) 307.1, 309.1 (M*+Na) Preparation 18 The following compounds are prepared in a similar manner to that of Preparation 17. (1) 2-[(4-Bromobutanoyl)amino]-3 -iodobenzamide 1H NMR (DMSO-d 6 , δ): 1.90-2.30 (2H, m), 2.43 (2H, t, J=7.4 Hz), 3.61 (2H, t, J=6.7 Hz), 7.10 (IH, t, J=7.8 Hz), 7.96 (IH, dd, J=1.3 Hz, J=7.8 Hz), 9.66 (IH, brs) Mass (ESI): 433.0 (M'+Na) (2) 3 -Bromo-2-[(4-bromobutanoyl)amino]benzamide 1H MR (DMSO-d 6 , δ): 1.80 - 2.10 (2H, m), 2.69 (2H, t, J=7.3 Hz), 3.51 (2H, t J=6.3 Hz), 7.10-9.70 (6H, m) Mass (ESI): 387.0 (M'+Na) (3) 2-[(4-Bromobutanoyl)amino]-3-ethylbenzamide 1H NMR (DMSO-de, δ): 0.90-3.80 (11H, m), 7.00-9.70 (6H, m) Mass (ESI): 335.1 (M + +H) (4) 2-[(4-bromobutanoyl)amino]-6-fluorobenzarnide MS (API-ES): 325.0 (M÷+Na) (5) 2-[(3-bromopropanoyl)amino]benzamide MS (API-ES): 293.1 (M'+Na) Preparation 19 A mixture of 2-aminobenzamide (45 mg), 4-(4-phenyl-3, 6-dihydro- l(2H)-pyridinyl)pentanoic acid (85.7 mg), O-(7-azabenzotriazol-l-yl)-N,N,N , ,N'-tetramethyluronium hexafluorophosphate (628 mg) and diisopropylethylamine (0.288 ml) was stirred at room temperature overnight. The mixture was diluted with water and extracted with dichloromethane three times. The combined extracts were washed with water three times, dried over magnesium sulfate and concentrated. The residue was purified by preparative thin layer chromatography using 10%) methanol in dichloromethane as an eluent to give the 2- { [4-(4-phenyl-3 , 6-dihydro- 1 (2H)-pyridinyl)pentanoyl]amino }benzamide. Mass (ESI): 388.3 (M + +H) Preparation 20 Under a nitrogen atmosphere, triethylamine (0.73 mL, 5.26 mmol) was added to a solution of 2-[(4-bromobutanoyl)amino]benzamide (500 mg, 1.75 mmol) and 4-phenyl-l,2,3,6-tetrahydropyridine hydrochloride (412 mg, 2.10 mmol) in N,N-dimethylformamide (5 mL) at 0 °C. The mixture was allowed to warm to room temperature and stirred for 24 hour. The reaction was quenched with water, and the product was extracted with chloroform. The organic layer was washed with water and dried over sodium sulfate. Purification over silica gel chromatography gave 2-{[4-(4-phenyl-3,6-dihydro-l(2H)-pyridinyl)butanoyl]amino}benzamide (477 mg, 74.8 %) as pale-yellow powder. 1H NMR (200MHz, CDC1 3 , δ): 2.01 (2H, quint, J=7.3 Hz), 2.41-2.56 (4H, m), 2.72 (2H, t, J=5.4 Hz), 3.76 (2H, d, J=5.7 Hz), 5.4-6.3 (2H, br), 6.05 (IH, m), 7.05 (IH, t, J=7.0 Hz), 7.21-7.37 (6H, m), 7.45-7.51 (2H, m), 8.64 (IH, d, J=8.6 Hz) Mass (APCI): 364.20 (M + +H) Preparation 21 The following compounds are prepared in a similar manner to that of Preparation 20. Preparation 22 The following compounds are prepared in a similar manner to that of Preparation 20. (1) 2-({4-[4-(4-methylphenyl)-l-piperidyl]butanoyl}amino)benzamide Mass (APCI): 379.93 (M + +H) (2) 2-{ [4-(4-phenyl- 1 -piperazinyl)butanoyl]amino}benzamide Mass (APCI): 367.07 (M'+H) Preparation 23 -(1) Palladium hydroxide on carbon (10%, 51.4mg, 0.0366mmol) was added to a solution of 2-({4-[4-[4-(methylthio)phenyl]-3,6-dihydro-l(2H)-pyridinyl]butanoyl}amino)benzamide (150 mg, 0.366 mmol) in a mixed solvent of methanol (2 mL) and ethyl acetate (2 mL). Purged by hydrogen (latm), the mixture was stirred at room temperature for 2 days. Purification over silica gel chromatography gave 2-[(4-{4-[4-(methylthio)phenyl]-l-piperidyl}butanoyl)amino]benzamide (44 mg, 29.2%) as product. Mass (APCI): 412.27 (M + +H) Preparation 23 -(2) Palladium on carbon (10%, 37.5 mg, 0.0352 mmol) was added to a solution of 2-{[4-(4-phenyl-3,6-dihydro-l(2H)-pyridinyl)butanoyl]amino}benzamide (128 mg, 0.352 mmol) in a mixed solvent of methanol (2 mL) and ethyl acetate (3 mL). Purged by hydrogen (1 atm), the mixture was stirred at room temperature for lOhour. Purification over silica gel chromatography gave 2-{[4-(4-phenyl-l-piperidyl)butanoyl]amino}benzamide (91 mg, 70.7 %) as product. Mass (APCI): 366.13 (M + +H) Preparation 24 The following compounds are prepared in a similar manner to that ofPreparation Preparation 25 The following compounds are prepared in a similar manner to that of Preparation 20. ( 1 ) 2- { [3 -(4-phenyl-3 ,6-dihydro- 1 (2H)-pyridinyl)propanoyl] amino }benzamide MS (APCI): 350.00 (M + +H) (2) 2-{[5-(4-phenyl-3,6-dihydro-l(2H)-pyridinyl)pentanoyl]amino}benzamide 1H MR (200MHz, CDC1 3 , δ): 1.6-1.9 (4H, m), 2.4-2.6 (6H, m), 2.71 (2H, t, J=5.4 Hz), 3.16 (2H, q, J=2.9 Hz), 5.4-6.5 (2H, br), 6.05 (IH, m), 7.07 (IH, t, J=7.5 Hz), 7.2-7.5 (5H, m), 7.5-7.6 (2H, m), 8.67 (IH, d, J=8.6 Hz), 11.17 (IH, br s) (3 ) 2- { [3 -(4-benzyl- 1 -piperidyl)propanoyl] amino Jbenzamide MS (APCI): 366.07 (M'+H) (4) 2- { [3 -(4-benzyl- 1 -piperazinyl)propanoyl] amino }benzamide MS (APCI): 367.00 (M + +H) Preparation 26 The following compounds are prepared in a similar manner to that of Preparation 20. Preparation 27 The following compounds are prepared in a similar manner to that of Preparation 10 23 -(2). Preparation 28 The following compounds are prepared in a similar manner to that of Preparation 20. (1) 2-({4-[4-(4-Chlorophenyl)-3-oxo-l-piperazinyl]butanoyl}amino)benzamide 1H NMR (DMSO-de, δ): 1.70 - 2.00 (2H, m), 2.20 - 2.70 (6H, m), 2.76 (2H, t, J=5.3 Hz), 3.60 (2H, t, J=5.3 Hz), 6.30 - 8.70 (10H, m), 11.71 (IH, brs) Mass (ESI): 437.3 (IVT+Na) (2) 2- { [4-(3 -phenyl- 1 -pyrrolidinyl)butanoyl] amino } benzamide Mass (APCI): 352.27 (M÷+H) (3 ) 2- { [4-(4-phenyl- lH-imidazol- 1 -yl)butanoyl] amino jbenzamide 1H MR (200MHz, CDC1 3 , δ): 2.25 (2H, quint, J=6.8 Hz), 2.44 (2H, t, J=6.1 Hz), 4.08 (2H, t, J=6.8 Hz), 6.0-6.9 (2H, br), 7.05 (IH, t, J=7.6 Hz), 7.1-7.7 (7H, m), 7.75 (2H, d, J=8.1 Hz), 8.62 (IH, d, J=8.4 Hz), 11.40 (IH, br s) (4) 2-{[4-(l,4,5,6-tetrahydrobenzo[f]isoquinolin-3(2H)-yl)butanoyl]amino}benzamide Mass (APCI): 389.73 (-vf+H) (5) 2- { [4-(spiro [ lH-indene- 1 ,4'-piperidin- 1 '-yl])butanoyl] amino } benzamide Mass (APCI): 390.13 (M + +H) (6) 2- { [4-(2, 3 -dihydrospiro[ lH-indene- 1 ,4'-piperidin- 1 '-yl])butanoyl] amino } - benzamide Mass (APCI): 392.20 (M + +H) Preparation 29 2-{[4-(4-phenyl-2,3,6,7-tetrahydro-lH-azepin-l-yl)butanoyl]amino}benzamide (142mg, 25.1%) and 2-{[4-(5-phenyl-2,3,4,7-tetrahydro-lH-azepin-l-yl)butanoyl]- amino}benzamide (121mg, 21.4%) were synthesized from 2-[(4-bromobutanoyl)- amino]benzamide (427mg, 1.50mmol) and a mixture of 5-phenyl-2,3,4,7-tetrahydro- lH-azepine hydrochloride and 4-phenyl-2,3,6,7-tetrahydro-lH-azepine hydrochloride (345mg, 1.65mmol) by a similar procedure to the Preparation 20. 2- { [4-(4-pheny 1-2, 3,6, 7-tetrahydro- 1 H-azepin- 1 -y l)butanoyl] amino } benzamide Mass (APCI): 378.20 (NT+H) 2- { [4-(5-pheny 1-2, 3,4, 7-tetrahydro- 1 H-azepin- 1 -y l)butanoyl] amino } benzamide Mass (APCI): 378.20 (M* " +H) Preparation 30 The following compounds are prepared in a similar manner to that of Preparation 23 -(21 (1) 2-{[4-(4-Phenylhexahydro-lH-azepin-l-yl)butanoyl]aniino}benzamide Mass (APCI): 380.27 (M + +H) (2) 2-{[4-(cis-l,4,4a,5,6,10b-hexahydrobenz[f]isoquinolin-3(2H)-yl)butanoyl]- amino}benzamide Mass (API-ES): 392.4 (M + +H) Preparation 31 Dimethylformamide (1.25 mL, 16.2 mmol) and oxaryl chloride (1.41 mL, 16.2 mmol) were added to a solution of 6-[(benzyloxy)carbonylamino]hexanoic acid (3.9 g, 14.7 mmol) in dichloromethane (5 mL) at 5 °C. The prepared 6-{[(benzyloxy)carbonyl]amino}hexanoyl chloride was added to a solution of 2-aminobenzamide and diisopropylethylamine (2.8mL, 1. leq) in dichrolomethane (5mL) at 5 °C. The mixture was stirred at room temperature for 2 hours. The mixture was extracted with AcOEt, and washed with saturated sodium hydrogen carbonate aqueous solution and brine. The organic layer was dried over MgSO and the solvent was removed in vacuo to give 2-{[5-[(benzyloxy)carbonylamino]hexanoyl]amino}benzamide (2.8 g, 7.3 mmol, 50 %) as yellow oil. Mass: 384 (M + +1) Example 1 l,2,3,6-Tetrahydro-4-phenylpyridine (54.8g, 280mmoi) was added to the 10% aqueous acetonitrile solution of 8-chloro-l-hydroxy-2,3-dihydropyrrolo[2, l-b]quinazoline-9(lH)-one (26.5g, 112mmmol), then sodium cyanoborohydride (10.5g, 168mmol) and acetic acid (8.9mL, 157mmol) was added to the reaction mixture. The mixture was stirred at room temperature over night. Saturated sodium hydrogen carbonate aqueous solution was added to the reaction mixture. The precipitate was corrected with filtration and purified by silica gel chromatography eluting with chloroform and methanol (100: 1-100:2). The resulting solid was recrystallized from 10% aqueous acetonitrile to give 5-chloro-2-[3-(4-phenyl-3,6-dihydro-l(2H)-pyridinyl)propyl]-4(3H)-quinazolinone (17g, 44mmol, 40%) as colorless fine needle. 1H NMR (300MHz, CDC1 3 , δ): 2.05 (2H, quint, J=6.2 Hz), 2.66 (2H, t, J=6.2 Hz), 2.80-2.92 (6H, m), 3.31 (2H, m), 6.118 (IH, s), 7.32-7.47 (6H, m), and 7.55 (2H, m). Mass (m/z): 380 (M'+l) Example 2 4-Phenylpiperidine hydrochloride (334mg, 1.69mmol) was added to the 10%) aqueous acetonitrile solution of 8-chloro-l-hydroxy-2,3-dihydropyrrolo[2, l-b]quinazoline-9(lH)-one (200mg, 0.85mmol), then sodium cyanoborohydride (133mg, 2.11 mmol) and acetic acid (0.1 mL, 1.69mmol) were added to the reaction mixture. The mixture was stirred at room temperature over night. The reaction mixture was extracted with ethyl acetate and washed with saturated sodium hydrogen carbonate aqueous solution and brine. The organic layer was dried over MgSO 4 and the solvent was removed in vacuo. The residue was purified by silica gel chromatography eluting with chloroform and methanol (100:5) to give 5-chloro-2-[3- (4-phenyl-l-piperidyl)propyl]-4(3H)-quinazolinone (96.6mg, 0.25mmol, 30%) as colorless solid. 1H NMR (300MHz, CDC1 3 , δ): 1.88 (2H, m), 2.00 (2H, m), 2.25 (2H, m), 2.28 (5H, m), 2.60 (2H, m), 2.86 (2H, m), 3.19 (2H, m), 7.33-7.41 (6H, m), and 7.53 (2H, m). Mass (m/z): 382 (M + +l) Example 3 4-Cyano-4-phenylpiperidine hydrochloride (452mg, 2.03mmol) was added to the 10%) aqueous acetonitrile solution of 8-chloro-l-hydroxy-2,3-dihydropyrrolo[2, l-b]quinazoline-9(lH)-one (160mg, 0.676mmol), then sodium cyanoborohydride (42.4mg, 0.676mmol) and acetic acid (46mL) were added to the reaction mixture. The reaction mixture was stirred at room temperature for 4 hours. The mixture was extracted with ethyl acetate and washed with saturated sodium hydrogen carbonate aqueous solution and brine. The organic layer was dried over magnesium sulfate and the solvent was removed in vacuo. The residue was purified by preparative TLC, and recrystallized from methanol to give 5-chloro-2-[3-(4-cyano-4-phenyl-l-piperidyl)propyl]-4(3H)-quinazolinone (22mg, 0.055mmol, 8%) as colorless powder. 1H NMR (300MHz, CDC1 3 , δ): 2.01(2H, quint, J= 5.5Hz), 2.12 (2H, m), 2.73-2.67 (6H, m), 2.92 (2H, m), 3.22 (2H, m), 7.43-7.48(4H, m), 7.54(2H, m) and 7.77 (2H, m) Mass (m/z): 407 (M*+l) I Example 4 4-Hydroxy-4-phenylpiperidine hydrochloride(592mg, 3.34mmol) was added to the 10% aqueous acetonitrile solution of 8-chloro- 1 -hydroxy-2,3 -dihydropyrrolo [2, 1 -b] quinazoline-9( lH)-one (395mg, 3.34mmol), then sodium cyanoborohydride (157mg, 2.5mmol) and acetic acid (0.15mL) were added to the reaction mixture. The reaction mixture was stirred at room temperature for 4 hours. The mixture was extracted with ethyl acetate and washed with saturated sodium hydrogen carbonate aqueous solution and brine. The organic layer was dried over magnesium sulfate and the solvent was removed in vacuo. The residue was purified by silica gel chromatography eluting with chloroform and methanol (100:5-50:50), and the obtained colorless solid was washed with ether to give 5-chloro-2-[3 -(4-hydroxy-4-phenyl- 1 -piperidyl)propyl]-4(3H)-quinazolinone ( 190mg, 0.48mmol, 29%) as colorless powder. 1H NMR (300MHz, CDC1 3 , δ): 1.82(2H, d, J= 5.5Hz), 2.01 (2H, m), 2.65-2.77 (6H, m), 2.90 (2H, m), 3.00 (2H, d, J=9.5 Hz), 7.30 (IH, dm, J=8.7Hz), 7.43-7.48(3H, m), 7.53(2H, m) and 7.71 (2H, dm, J=7.3 Hz) Mass (m/z): 398 (M÷+l) Example 5 4-Amino-4-phenylpiperidine (150mg, 0.85mmol) was added to 10% aqueous acetonitrile solution of 8-chloro- 1 -hydroxy-2, 3 -dihydropyrrolo[2, 1 -b]quinazoline-9( lH)-one (181 mg, 0.77mmol) . NaBHsCN (64.1mg, 1.02mmol) and AcOH (0.146mL, 2.55mmol) were added to the mixture, and the mixture was stirred at room temperature for 4 hours. The reaction mixture was extracted with AcOEt, washed with saturated sodium hydrogen carbonate aqueous solution. Residual solid was purified by preparative TLC (chloroform/methanol 75:25) to give 2-[3-(4-amino-4-phenyl-l-piperidyl)propyl]-5-chloro-4(3H)-quinazolinone (3.5mg, 0.008mmol, 1%) as colorles powder. 1H NMR (300MHz, CDC1 3 , δ): 1.86 (2H, m), 1.97 (2H, m), 2.58 (4H, m), 2.74 (4H, m) 3 2.86 (2H, m), 7.25 (Hi m), 7.38 (3H, m), 7.52 (2H, m), and 7.63 (2H, d, J=7.8 Hz). Mass (m/z): 397 (Ivf+1) Example 6 To a solution of 2-[4-(l-phenyl-4-piperidyl)-butanoylamino]benzamide in 1,4-dioxane (6 mL) was added IN aqueous NaOH (6 mL). The mixture was stirred for 1 hour at room temperature, then H 2 O was added and neutralized with IN aqueous HCl. A white precipitate was filtered ,washed with Et 2 O and dried at 40 °C to give 2-[3-(l-phenyl-4-piperidyl)propyl]-4(3H)-quinazolinone (75 mg, 0.21 mmol, 79%) as a pale yellow powder. 1H NMR (300MHz, CDC1 3 , δ): 1.29-1.55 ( 5H, m), 1.84 ( 2H, d, J=10.6 Hz), 1.89-2.04 (2H, m), 2.68 ( 2H, t, J=10.0 Hz), 2.80 (2H, t, J=7.7 Hz), 3.66 ( 2H,d, 12.8 Hz), 6.82 (IH, t, J=7.0 Hz), 6.93 ( 2H, d, J=6.9 Hz), 7.15-7.30 ( 2H, m), 7.47 ( IH, t, J=8.1 Hz), 7.66-7.85 ( 2H, m), 8.29 (IH, d, J=8.1 Hz), 11.36 ( IH, s) Mass: 348 (M ) Example 7 A mixture of 3 -nitrois atoic anhydride (0.11 g) and 4-(4-phenyl-3, 6-dihydro- l(2H)-pyridinyl)butanimidamide (154 mg) in pyridine was refluxed for 24 hours. The mixture was diluted with water and extracted with dichloromethane three times. The combined extracts were dried over magnesium sulfate, concentrated and co-evaporated with toluene twice. The residue was purified by preparative thin layer chromatography on silica gel using 10% methanol in dichloromethane as an eluent to give 8-nitro-2-[3 -(4-phenyl-3 ,6-dihydro- 1 (2H)-pyridinyl)propyl]-4(3H)-quinazolinone as a yellow powder. 1H NMR (DMSO-d 6 , δ): 1.80-2.10 (2H, m), 2.40-3.30 (10H, m), 6.02 (Hi s), 7.10-8.60 (8H, m). Mass (ESI): 391.2 (M÷+H) Example 8 Under a nitrogen atmosphere, triethylamine (1.39 mL, 10.0 mmol) was added to a solution of 2-[(4-bromobutanoyl)amino]benzamide (285 mg, 1.00 mmol) and 4-phenyl-4-piperidinol (266 mg, 1.50 mmol) in N,N-dimethylformamide (3 mL) at 0 °C. The mixture was allowed to warm to room temperature and stirred for 13 hours. The reaction was quenched with water, and the product was extracted with chloroform. The organic layer was washed with water and dried over sodium sulfate. The crude 2-{[4-(4-hydroxy-4-phenyl-l-piperidyl)butanoyl]amino}benzamide was dissolved in dioxane (3 mL). An aqueous solution of sodium hydroxide (IM, 3 mL) was added to the solution at room temperature, and the mixture was stirred at that temperature for 3 hour. The organic materials were extracted with chloroform, and the organic layer was washed with water and dried over sodium sulfate. Recrystalization of the crude product from chloroform-methanol gave 2-[3-(4-hydroxy-4-phenyl-l-piperidyl)propyl]-4(3H)-quinazolinone (223 mg, 61.4%). 1H NMR (200MHz, CDCl 3j δ): 1.7-1.9 (4H, m), 2.00 (2H, quint, J=5.4 Hz), 2.6-2.8 (5H, m), 2.9-3.1 (4H, m), 7.29 (2H, t, J=6.2 Hz), 7.42 (3H, t, J=7.4 Hz), 7.64 (IH, t, J=6.8 Hz), 7.73 (2H, d, J=8.1 Hz), 8.28 (IH, d, J=7.9 Hz) Mass (APCI): 364.00 (M + +H) Example 9 2-{[4-(4-Phenyl-3,6-dihydro-l(2H)-pyridinyl)butanoyl]amino}benzamide (475 mg, 1.31 mmol) was dissolved in dioxane (5 mL). An aqueous solution of sodium hydroxide (IM, 3.92 mL) was added to the solution at room temperature, and the mixture was stirred at that temperature for 15 hours. The organic materials were extracted with chloroform, and the organic layer was washed with water and dried over sodium sulfate. Recrystalization of the crude product from chloroform-methanol gave 2- { 3 - [4-phenyl-3 ,6-dihydro- 1 (2H)-pyridinyl]propyl } -4(3H)-quinazolinone (329 mg, 72.9 %). 1H NMR (200MHz, CDC1 3 , δ): 2.05 (2H, quint, J=6.0 Hz), 2.66 (2H, t, J=6.0 Hz), 2.81-2.94 (4H, m), 3.31 (2H, d, J=3.2 Hz), 6.12 (IH, t, J=2.9 Hz), 7.21-7.49 (7H, m), 7.61-7.72 (2H, m), 8.23 (IH, d, J=6.6 Hz) Mass (APCI): 346.20 (M*+H) Example 10 The following compounds are prepared in a similar manner to that of Example 9. If necessary, the starting compounds of them were prepared in similar manners of Preparation 17. Preparation 20 and preparation 23 -(2) Example 11 The following compounds are prepared in a similar manner to that of Example 9. If necessary, the starting compounds of them were prepared in similar manners of Preparation 17. Preparation 20 and preparation 23 -(2) Example 12 The following compounds are prepared in a similar manner to that of Example 9. If necessary, the starting compounds of them were prepared in similar manners of Preparation 17 and Preparation 20. Example 13 The following compounds were prepared in a similar manner to that of Example 9. If necessary, the starting compounds of them were prepared in similar manners of Preparation 17 and Preparation 20. Example 14 The following compounds are prepared in a similar manner to that of Example 9. If necessary, the starting compounds of them were prepared in similar manners of Preparation 17 and Preparation 20. Example 15 A mixture of 8-chloro-2-[3-(4-phenyl-3,6-dihydro-l (2H)-pyridinyl)propyl]- 4(3H)-quinazolinone (50 mg), 1-methylpiperazine (19.8 mg), palladium (II) acetate (2.96 mg), 2-(di-t-butylphosphino)biphenyl (7.86 mg), sodium t-butoxide (23 mg) in toluene (0.4 ml) and tetrahydrofuran (0.2 ml) was stirred at ' 80 °C under nitrogen atmosphere overnight. The mixture was cooled, diluted with water and extracted with dichloromethane twice. The combined extracts were dried over magnesium sulfate and concentrated. The residue was purified by preparative thin layer chromatography on silica gel using 10% methanol in dichloromethane to give the 8-(4-methyl-l-piperazinyl)-2-[3-(4-phenyl-3,6-dihydro- l(2H)-pyridinyl)propyl]-4(3H)-quinazolinone. Mass (APCI): 444.3 (M + +H) Example 16 The following compounds are prepared in a similar manner to that of Example 15. Example 17 To a suspension of 8-nitro-2-[3-(4-phenyl-3,6-dihydro-l(2H)-pyridinyl)propyl]-4(3H)-quinazolinone (50 mg) in ethanol (10 ml) and water (5 ml) were added iron powder (57 mg) and ammonium chloride (5.8 mg). After stirring under reflux for 1 hour, the mixture was filtered and the filtrate was concentrated. The residue was purified by preparative thin layer chromatography using 10% methanol in dichloromethane as an eluent to give 8-Amino-2-[3 -(4-phenyl-3 ,6-dihydro- 1 (2H)-pyridinyl)propyl]-4(3H)-quinazolinone as a brown powder. 1H NMR (DMSO-de, δ): 1.80 - 2.20 (2H, m), 2.30 - 3.30 (10H, m), 5.58 (2H, brs), 6.13 (IH, s), 6.80 - 7.70 (8H, m), 12.03 (IH, brs) Mass (ESI): 361.4 Ovf+H) Example 18 A slurry of 8-amino-2-[3 -(4-phenyl-3 ,6-dihydro- 1 (2H)-pyridinyl)propyl]-4(3H)-quinazolinone (40 mg), 37% aqueous formaldehyde (0.088 ml), acetic acid (0.032 ml) and sodium cyanoborohydride (70 mg) in acetonitrile (10 ml) was stirred at room temperature overnight. The reaction was quenched with aqueous sodium hydrogen carbonate and extracted with dichloromethane three times. The combined extracts were dried over magnesium sulfate and concentrated. The residue was purified by preparative thin layer chromatography using 10% methanol in dichloromethane as an eluent to give 8-dimethylamino-2-[3 -(4-phenyl-3 ,6-dihydro- 1 (2H)-pyridinyl)propyl]-4(3H)-quinazolinon e (18 mg) as a yellow solid. 1H NMR (DMSO-de, δ): 1.80 - 2.20 (2H, m), 2.30 - 2.90 (10H, m), 2.96 (6H, s), 6.15 (Hi s), 7.00 - 7.70 (8H, m), 12.15 (IH, brs) Mass (ESI): 389.4 (M'+H) Example 19 The following compounds are prepared in a similar manner to that of Preparation 18. ( 1 ) 8-benzylamino-2- { 3 -[4-phenyl-3 , 6-dihydro- 1 (2H)-pyridinyl]propyl) - 4(3H)-quinazolinone 1H NMR (200MHz, DMSO-de, δ): 1.8-2.1 (2H,m), 2.1-3.0 (8H, m), 3.0-3.2 (2H, m), 4.47 (2H, d, J = 6Hz), 6.09 (IH, m), 6.56 (Hi t, J = 6.2Hz), 6.69 (Hi d, J = 6.2Hz), 7.0-7.5 (12H, m) Mass: 451 (M + +H) Example 20 A solution of 8-amino-2-[3-(4-phenyl-3,6-dihydro-l(2H)-pyridinyl)propyl]-4(3H)-quinazolinone (30 mg) and acetic anhydride (17 mg) in dichloromethane was stirred at room temperature overnight. The mixture was concentrated and purified by preparative thin layer chromatography (10% methanol in dichloromethane) to give N-{4-Oxo-2-[(4-phenyl-3,6-dihydro- l(2H)-pyridinyl)propyl]-3,4-dihydro-8-quinazolinyl}acetamide as a pale yellow powder. 1H MR (200MHz, DMSO-de, δ): 1.80 - 2.20 (2H, m), 2.22 (3H, s), 2.30 - 3.00 (8H, m), 3.10 (2H, d, J=3.0 Hz), 6.10 (Hi s), 7.10 - 7.60 (6H, m), 7.70 (IH, dd, J=1.4, 8.0 Hz), 8.57 (Hi dd, J=1.4, 8.0 Hz), 9.51 (IH, s), 12.38 (IH, brs). Mass (ESI): 403.4 (M'+H) Example 21 A mixture of 8-iodo-2-[3-(4-phenyl-3,6-dihydro-l(2H)-pyridinyl)propyl]-4(3H)-quinazolinone (45 mg), (trimethylsilyl)acetylene (14.1 mg), dichlorobis(triphenylphosphine)palladium (II) (6.7 mg), copper iodide (1.82 mg) and triethylamine (0.027 ml) in N,N-dimethylformamide was stirred at room temperature under nitrogen overnight. The mixture was diluted with water and extracted with dichloromethane twice. The combined extracts were washed with water twice, dried over magnesium sulfate and concentrated. The residue was purified by preparative thin layer chromatography using 10% methanol in dichloromethane as an eluent to give 2-[3-(4-Phenyl-3,6-dihydro-l(2H)-pyridinyl)propyl]-8-[(trimethylsilyl)ethynyl]- 4(3H)-quinazolinone as a colorless powder (13 mg). 1H MR (200MHz, CDC1 3 , δ): 0.33 (9H, s), 0.70 - 3.30 (12H, m), 6.08 (IH, s), 7.10 - 8.30 (8H, m) Mass (ESI): 441.64 (M + +H) Example 22 A solution of 2-[3-(4-Phenyl-3, 6-dihydro- l(2H)-pyridinyl)propyl]- 8-[(trimethylsilyl)ethynyl]-4(3H)-quinazolinone (202 mg) in methanol was stirred at room temperature in the presence of potassium carbonate (190 mg) for 3 hours. The mixture was diluted with water and extracted with dichloromethane twice. The combined extracts were dried over magnesium sulfate and concentrated. The residue was purified by preparative thin layer chromatography on silica gel using 10% methanol in dichloromethane as an eluent to give 8-Ethynyl-2-[3-(4-phenyl-3,6-dihydro-l(2H)-pyridinyl)propyl]-4(3H)-quinazolinone the objective compound, which was converted to the corresponding hydrochloride salt (59 mg) by treatment of 4N hydrogen chloride in ethyl acetate. lH NMR (DMSO-d6, d): 2.10 - 2.40 (2H, m), 2.60 - 3.00 (4H, m), 3.00 - 4.20 (6H, m), 4.51 (Hi s), 6.22 (IH, s), 7.10 - 7.80 (6H, m), 7.94 (IH, dd, J=1.5, 7.9 Hz), 8.11 (IH, dd, J=1.5, 7.9 Hz), 10.32 (IH, brs), 12.44 (IH, brs) Mass (APCI): 370.07 (M* " +H) Example 23 The following compounds are prepared in a similar manner to that of Example 21. ( 1 ) 8-phenyl-2- { 3 -[4-ρhenyl-3 , 6-dihydro- 1 (2H)-ρyridinyl]proρyl } - 4(3H)-quinazolinone 1HNMR (200MHz, DMSO-d 6 , δ): 1.8-2.1 (2H,m), 2.1-3.0 (8H, m), 3.0-3.2 (2H, m), 6.09 (IH, m), 7.0-8.2 (13H, m) Mass: 422 (M + +H) Example 24 Under a nitrogen atmosphere, (diethylamino)sulfur trifluoride (0.363 mL, 2.75 mmol) was added dropwise to a solution of 2-[3-(4-hydroxy-4-phenyl-l-piperidyl)propyl]-4(3H)-quinazolinone (100 rag, 0.275 mmol) in dichloromethane (lOmL) at -78 °C. The mixture was stirred for 2 hours (to -50 °C). (Diethylamino)sulfer trifluoride (0.363mL, 2.75mmol) was added, and the mixture was stirred for further 2h (to 0 o C). Quenched with saturated aqueous sodium hydrogencarbonate, the organic materials were extracted with ethyl acetate. Purification over silica gel chromatography gave 2-[3-(4-fluoro-4-phenyl-l-piperidyl)propyl]-4(3H)-quinazolinone (34mg, 33.8%)). 1H NMR (200MHz, CDC1 3 , δ): 1.9-2.1 (4H, m), 2.5-2.9 (6H, m), 2.9-3.1 (4H, m), 7.31 (IH, t, J=7.1 Hz), 7.44 (3H, t, J=7.9 Hz), 7.6-7.8 (4H, m), 8.29 (IH, d, J=7.9 Hz). MS (APCI): 365.80 (IVT+H) Example 25 2-{3-[4-phenyl-3,6-dihydro-l(2H)-pyridinyl]proρyl}-4(3H)-quinazolinone (110 mg, 0.310 mmol) was suspended in a mixed solvent of chloroform (1 mL) and ethyl acetate (2 mL). To this suspension, a solution of hydrogen chloride (4M, 2.33 mL) was added, and the mixture was stirred for lhour. The white precipitate was collected by filtration to give 2-{3-[4-phenyl-3,6-dihydro-l(2H)-pyridinyl]propyl}-4(3H)-quinazolinone hydrochloride (124 mg, 104 %) as product. 1H NMR (200MHz, DMSO-de, δ): 2.29 (2H, quint, J=7.6 Hz), 2.8-2.9 (4H, m), 3.30 (2H, dd, J=8.6, 6.8 Hz), 3.5-4.2 (4H, m), 6.21 (IH, br s), 7.2-7.6 (6H, m), 7.73 (IH, d, J=7.7 Hz), 7.86 (IH, t, J=6.9 Hz), 8.13 (IH, d, J=7.9 Hz). MS (APCI): 346.13 (M + +H) Example 26 The following compounds are prepared in a similar manner to that of Preparation 25. (1) 8-chloro-2-{3-[4-(4-acetylphenyl)-3,6-dihydropyridin-l(2H)-yl]propyl}- 4(3H)-quinazolinone hydrochloride 1H NMR (200MHz, DMSO-d 6 , δ): 2.1-2.4 (2H, m), 2.59 (3H, s), 2.7-3.0 (4H, m), 3.2-3.5 (3H, m), 3.6-4.2 (3H, m), 6.40 (IH, br s), 7.46 (Hi t, J=7.8 Hz), 7.65 (2H, d, J=8.4 Hz), 7.9-8.0 (3H, m), 8.06 (Hi d, J=7.9 Hz), 10.65 (IH, br), 12.54 (IH, br) Mass (APCI): 422.07 (M'+H) (2) 8-chloro-2- { 3 -[4-phenyl-3 , 6-dihydropyridin- 1 (2H)-yl]propyl } - 4(3 H)-quinazolinone hydrochloride 1H NMR (200MHz, DMSO-d 6 , δ): 2.1-2.45 (2H, m), 2.65-3.05 (4H, m), 3.15-3.45 (3H, m), 3.55-3.9 (2H, m), 3.95-4.15 (IH, m), 6.20 (IH, s), 7.3-7.55 (6H, m), 7.95 (IH, dd, J=7.8, 1.4 Hz), 8.05 (IH, dd, J=7.8, 1.4 Hz) (3) 8-chloro-2-{3-[4-[4-(tifluoromethyl)ρhenyl]-3,6-dihydroρyridin-l(2H)-yl]proρyl}- 4(3H)-quinazolinone hydrochloride 1H NMR (DMSO-de, δ): 2.15-2.35 (2H, m), 2.75-2.95 (4H, m), 3.25-3.45 (2H, m), 3.45-4.20 (4H, m), 6.37 (IH, s), 7.45 (IH, t, J=7.8 Hz), 7.73 (4H, s), 7.94 (IH, dd, J=7.8, 1.4 Hz), 8.05 (Hi dd, J=7.8, 1.4 Hz), 10.59 (IH, br s), 12.53 (IH, br s) (4) 8-Chloro-2-{3-[4-(4-(hydroxymethyl)phenyl)-3,6-dihydropyridin-l(2H)-yl]- propyl}4(3H)-quinazolinone hydrochloride 1H NMR (DMSO-d 6 , δ): 2.15-2.40 (2H, m), 2.7-2.9 (4H, m), 3.6-4.2 (6H, m), 4.50 (2H, s), 5.72 (IH, s), 6.18 (IH, s), 7.32 (2H, d, J=8.3 Hz), 7.4-7.5 (3H, m), 7.94 (IH, dd, J=7.8, 1.4 Hz), 8.06 (IH, dd, J=7.8, 1.4 Hz), 10.59 (IH, br s), 12.53 (IH, br s) Example 27 Under a nitrogen atmosphere, IM boron tribromide in dichloromethane (1.99 ml) was added to a solution of 2-{3-[4-(4-methoxyphenyl)piperidin-l-yl]propyl}-4(3H)-quinazolinone (150 mg) in dichloromethane (7.5 ml) at 0 °C. The mixture was stirred for 2 hours and the solvent was evaporated. The residue was diluted with aqueous sodium hydrogencarbonate and the aqueous phase was removed with decant. The crude product was triturated with a mixture of chloroform and methanol (10: 1) and the resulting precipitate was collected by filtration. The precipitate was washed with chloroform-methanol and dried under reduced pressure to afford 2-{3-[4-(4-hydroxyphenyl)piperidin-l-yl]propyl}-4(3H)-quinazolinone (122 mg) . 1H NMR (200MHz, DMSO-d 6 , δ): 1.7-2.1 (4H, m), 2.1-2.3 (2H, m), 2.6-3.3 (9H, m), 6.72 (2H, d, J=8.5 Hz), 6.90 (2H, d, J=8.5 Hz), 7.51 (IH, dt, J=8.1, 1.1 Hz), 7.63 (Hi d, J=8.0 Hz), 7.82 (IH, dt, J=8.4, 1.5 Hz), 8.11 (IH, dd, J=7.9, IT Hz) Mass: 361.800^) Example 28 The following compounds are prepared in a similar manner to that of Example 27. (1) 2-{3-[4-(4-hydroxyphenyl)-3,6-dihydropyridin-l(2H)-yl]propyl}- 4(3H)-quinazolinone 1H NMR (DMSO-de, δ): 2.1-2.4 (2H, m), 2.65-2.95 (4H, m), 3.2-3.5 (3H, m), 3.6-4.2 (3H, m), 6.03 (IH, s), 6.77 (2H, d, J=8J Hz), 7.32 (2H, d, J=8.7 Hz), 7.56 (IH, X, J=7.3 Hz), 7.67 (Hi d, J=8.1 Hz), 7.85 (IH, t, J=7.4 Hz), 8.14 (IH, dd, J=7.8, 1.2 Hz) Mass: 362.3 (M'+H) Example 29 Under a nitrogen atmosphere, dimethylsulfoxide (0.093 ml) in dichloromethane was added to a stirred solution of oxalylchloride (0.06 ml) in dichloromethane (10 ml) at -78 °C. The mixture was stirred for 1 hour. To this solution was added a solution of 2- { 3 - [4-(4-hydroxymethy l)phenyl] -3 , 6-dihy dropyridin- 1 (2H)-yl } propyl } - 4(3H)-quinazolinone (130 mg) in a mixture of dichloromethane (1.5 ml) and dimethylsulfoxide (0.5 ml) at -70 °C. The mixture was stirred for 30 minutes and to this solution was added triethyl amine (0.25 ml) at the same temperature. The whole mixture was gradually warmed to -20 °C and the reaction was quenched with water. The aqueous layer was separated and the organic layer was washed with brine, dried over magnesium sulfate. After evaporation of the solvent, the residue was purified by preparative TLC eluting with chloroform-methanol to afford 2-{3-[4-(4-formylphenyl)-3,6-dihydropyridin-l(2H)-yl]propyl}-4(3H)-quinazolinone (47mg). 1H MR (200MHz, DMSO-de, δ): 1.85-2.1 (2H, m), 2.4-2.8 (10H, m), 3.12 (2H, d, J=2.8 Hz), 6.35 (Hi s), 7.42 (IH, t, J=6.9 Hz), 7.5-7.65 (3H, m), 7.7-7.8 (IH, m), 7.86 (2H, d, J=8.3 Hz), 8.04 (IH, dd, J=7.9, 1.3 Hz), 9.97 (IH, s), 12.21 (IH, br s) Mass: 374.0 (M + ) Example 30 3 -Chloro-2-( { 4- [4-(4-cyanophenyl)-3 , 6-dihydro- 1 (2H)-pyridinyl]butanoyl } amino) benzamide (152 mg, 0.359 mmol) was dissolved in a mixed solvent of dioxane (2 mL) and methanol (3 mL). An aqueous solution of sodium hydroxide (1 M, 1.08 mL) was added to the solution at room temperature, and the mixture was stirred at that temperature for lhour. The organic materials were extracted with chloroform, and the organic layer was washed with water and dried over sodium sulfate. The crude product was suspended in a mixed solvent of chloroform (lmL) and ethyl acetate (2mL). To this suspension, a solution of hydrogen chloride (4M, 2,0mL) was added, and the mixture was stirred for lhour. The white precipitate was collected by filtration to give 8-chloro-2-{3-[4-(4-cyanophenyl)- 3,6-dihydropyridin-l(2H)-yl]propyl}-4(3H)-quinazolinone (140mg, 88.3%) as product. 1H MR (200MHz, DMSO-de, δ): 2.1-2.3 (2H, m), 2.7-2.9 (4H, m), 3.2-3.4 (3H, m), 3.7-4.0 (2H, m), 4.0-4.2 (IH, m), 6.44 (IH, br s), 7.46 (Hi t, J=7.9 Hz), 7.7.0 (2H, d, J=8,5 Hz), 7.87 (2H, d, J=8.4 Hz), 7.95 (IH, d, J=7.8 Hz), 8.06 (Hi d, J=7.9 Hz), 10.51 (IH, br), 12.53 (Hi br) Mass (APCI): 405.07 Vf+H) Example 31 The following compounds are prepared in a similar manner to that of Example 9, If necessary, the starting compounds of them were prepared in similar manners of Preparation 17 and Preparation 20. Example 32 The following compounds are prepared in a similar manner to that of Example 9. If necessary, the starting compounds of them were prepared in similar manners of Preparation 17. Preparation 20 and preparation 23 -(2) Example 33 The following compounds are prepared in a similar manner to that of Example 9. If necessary, the starting compounds of them were prepared in similar manners of Preparation 17 and Preparation 20. Example 34 The following compounds are prepared in a similar manner to that of Example 9. If necessary, the starting compounds of them were prepared in similar manners of Preparation J7 and Preparation 20. Example 35 The following compounds are prepared in a similar manner to that of Example 9. If necessary, the starting compounds of them were prepared in similar manners of Preparation 17 and Preparation 20 Example 36 The following compounds are prepared in a similar manner to that of Example 9. If necessary, the starting compounds of them were prepared in similar manners of Preparation 17 and Preparation 20. Example 37 The following compounds are prepared in a similar manner to that of Example 25. (1) 8-Chloro-2-{3-[4-(2-thienyl)-3,6-dihydro-l(2H)-pyridinyl]propyl}- 4(3H)-quinazolinone hydrochloride i MR (200MHz, DMSO-de, δ): 2.1-2.4 (2H, m), 2,7-2.9 (4H, m), 3.1-3.4 (2H, m), 3.4-3.8 (3H, m), 3.9-4.1 (Hi m), 6.10 (IH, br s), 7.07 (Hi d, J=3.6 Hz), 7.20 (IH, d, J=3.6 Hz), 7.4-7.6 (2H, m), 7.95 (IH, d, J=7.8 Hz), 8.06 (IH, d, J=7.8 Hz), 10.20 (Hi br), 12.51 (Hi br s) Mass (APCI): 385.80 (Ivf +H) (2) 8-Chloro-2-{3-[4-(3-thienyl)-3,6-dihydro-l(2H)-pyridinyl]propyl}- 4(3H)-quinazolinone hydrochloride 1H NMR (200MHz, DMSO-d 6 , δ): 2.21 (2H, quint, J=8.2 Hz), 2.79 (4H, t, J=6.8 Hz), 3.1-3.4 (3H, m), 3.7-3.9 (2H, m), 3.9-4.1 (IH, m), 6.09 (Hi br s), 7.07 (IH, dd, J=7.0, 3.6 Hz), 7.19 (Hi d, J=3.0 Hz), 7.4-7.6 (2H, m), 7.95 (Hi d, J=7.8 Hz), 8.06 (IH, d, J=7.9 Hz), 10.53 (Hi br), 12.52 (IH, br s) Mass (APCI): 385.80 (M'+H) (3) 8-Chloro-2-{3-[4-(4-pyridinyl)-3,6-dihydro-l(2H)-pyridinyl]propyl}- 4(3H)-quinazolinone dihydrochloride 1H NMR (DMSO-de, δ): 6.79 (IH, s), 7.45 (IH, t, J=7.9 Hz), 7.87 (2H, d, J=6.6 Hz), 7.94 (Hi dd, J=7.9,1.4 Hz), 8.06 (IH, dd, J=7.9, 1.4 Hz), 8.77 (2H, d, J=6.6 Hz), 12.52 (IH, br s) Example 38 The following compounds are prepared in a similar manner to that of Example 9. If necessary, the starting compounds of them were prepared in similar manners of Preparation 17 and Preparation 20. Example 39 The following compounds are prepared in a similar manner to that of Example 9. If necessary, the starting compounds of them were prepared in similar manners of Preparation 17 and Preparation 20. Example 40 The following compounds are prepared in a similar manner to that of Example 9. If necessary, the starting compounds of them were prepared in similar manners of Preparation 17 and Preparation 20. (1) 2-[(l-ethyl-3-azetidinyl)methyl]-4(3H)-quinazolinone 1H NMR (200MHz, CDC1 3 , δ): 1.04 (3H, t, J = 7Hz), 2.5-3.3 (9H, m), 7.4-8.2 (4H, m) Mass: 244 Qvf+H) (2) 2-[(l-ethyl-3-pyrrolidinyl)methyl]-4(3H)-quinazolinone 1H NMR (200MHz, DMSO-de, δ): 1.06 (3H, t, J = 8Hz), 2.2-2.8 (7H, m), 7.4-8.2 (4H, m) Mass: 258 (Ivf+H) (3 ) 2- { [ 1 -(3 -phenylpropyl)-3 -pyrrolidinyl] methyl } -4(3H)-quinazolinone 1HNMR (200MHz, DMSO-de, δ): 1.6-1.9 (2H, m), 2.1-2.8 (10H, m), 7.0-7.3 (5H, m), 7.48 (IH, t, J = 8Hz), 7.59 (IH, d, J = 8Hz), 7.75 (IH, t, J = 8Hz), 8.11 (IH, d, J = 8Hz) Mass: 348(M + +H) (4) 2-[(l-ethyl-4-piperidyl)methyl]-4(3H)-quinazolinone 1H NMR (200MHz, DMSO-de, δ): 0.95 (3H, t, J = 7Hz), 1.5-2.2 (4H, m), 2.32 (2H, q, J = 7Hz), 7.41 (IH, t, J = 8Hz), 7.52 (IH, d, J = 8Hz), 7.80 (Hi t, J = 8Hz), 8.08 (IH, d, J = 8Hz) Mass: 272 (M + +H) (5) 2-{3-[4-ethynyl-3,6-dihydro-l(2H)-pyridinyl]propyl}-4(3H)-quinazolinone 1H NMR (200MHz, DMSO-de, δ): 1.7-2.2 (4H, m), 2.5-2.7 (2H, m), 2.7-2.9 (2H, m), 6.04 (IH, m), 7.40 (IH, t, J = 8Hz), 7.57 (IH, d, J = 8Hz), 7.75 (Hi t, J =8Hz), 8.06 (Hi d, J = 8Hz) Mass: 294 Ovf+H) (6) 2- { 3 -[4-phenylethynyl-3 , 6-dihydro- 1 (2H)-pyridinyl]propyl } -4(3H)-quinazolinone 1H NMR (200MHz, DMSO-d 6 , δ): 1.8-2.0 (2H, m),2.6-2.8 (4h, m), 3.78 (2H, s), 7.2-8.2 (11H, m) Mass: 413 vf+H) (7) 2- { 3 -[4-( 1 -naphthylmethyl)- 1 -piperazinyl]propyl } -4(3H)-quinazolinone 1HNMR (200MHz, DMSO-d 6 , δ): 1.7-2.0 (2H, m), 2.2-2.4 (2H, m), 2.5-2.8 (6H, m), 3.0-3.2 (2H, m), 6.12 (IH, m), 7.3-7.5 (6H, m), 7.59 (Hi d, J = 8Hz), 7.77 (IH, t, J =8Hz), 8.06 (IH, d, J = 8Hz) Mass: 370 ( f+H) (8) 2- {3- [4-(ethylsulfonyl)- 1 -piperazinyljpropyl } -4(3H)-quinazolinone 1H NMR (200MHz, DMSO-dg, δ): 1.14 (3H, t, J = 7.5Hz), 1.8-2.0 (2H, m), 2.5-2.8 (4H, m), 2.99 (2H, q, J = 7.5Hz), 3.0-3.3 (4H, m), 7.40 (IH, t, J = 8Hz), 7.52 (IH, d, J = 8Hz), 7.75 (IH, t, J = 8Hz), 8.09 (IH, d, J =8Hz) Mass: 365 (Ivf+H) (9) 2- {3 -[4-(2-furoyl)- 1 -piperazinyljpropyl } -4(3H)-quinazolinone 1H NMR (200MHz, DMSO-de, δ): 1.8-2.0 (2H, m), 2.2-2.8 (8H, m), 6.6-6.7 (IH, m), 6.9-7.0 (IH, m), 7.48 (IH, t, J = 8Hz), 7.68 (IH, d, J = 8Hz), 7,7-7.9 (2H, m), 8.09 (IH, m) Mass: 367 (M^+H) (10) 2-[3-(4-benzoyl-l-piperidyl)propyl]-4(3H)-quinazolinone 1HNMR (200MHz, DMSO-de, δ): 1.4-3.0 (15H, m), 7.4-7.9 (6H, m), 7.92 (2H, d, J = 8Hz), 8.06 (IH, d, J =8Hz) Mass: 376 (M÷+H) (11) 2-[3-(4-Phenyl-3,6-dihydro-l(2H)-pyridinyl)butyl]-4(3H)-quinazolinone Mass (ESI): 360.3 (M'+H) Example 41 The following compounds are prepared in a similar manner to that of Example 25. If necessary, the starting compounds of them were prepared in similar manners of Preparation 17. Preparation 20. preparation 23 -(2) and Example 9. (1) 2-(3-azetidinylmethyl)-4(3H)-quinazolinone hydrochloride 1H NMR (200MHz, DMSO-de, δ): 2.8-3.8 (5H, m), 7.4-8.2 (4H, m) Mass: 202 (M + +H) (2) 2-(3-pyrrolidinylmethyl)-4(3H)-quinazolinone hydrochloride 1H NMR (200MHz, DMSO-de, δ): 1.6-1.9 (2H, m), 2.0-2.2 (2H, m), 2.3-3.3 (5H, m), 7.5-8.3 (4H, m) Mass: 230 (M +H) (3) 2-(4-piperidylmethyl)-4(3H)-quinazolinone hydrochloride 1HNMR (200MHz, DMSO-d 6 , δ): 1.5-2.3 (5H, m), 2.6-3.2 (6H, m), 7.5-8.0 (3H, m), 8.15 (lH, d, J = 8Hz) Mass: 244 (M'+H) Example 42 2-{[5-[(Benzyloxy)carbonylamino]hexanoyl]amino}benzamide (2.8 g, 7.3 mmol) was dissolved in IN NaOH (36.5 mL) and dioxane. The reaction mixture was stirred at room temperature for 2 hours. The mixture was acidified with 6N HCl aqueous solution and extracted with AcOEt, washed with brine. The organic layer was dried over MgSO and the solvent was removed in vacuo. The obtained powder was washed with ether to give 2-{5-[(benzyloxy)carbonylamino]pentyl}-4(3H)-quinazolinone as colorless powder (1.99 g, 5.4 mmol, 75 %) i NMR (300MHz, CDC1 3 , δ): 1.48 (2H, t, J=7.9 Hz), 1.60 (2H, m), 1.89 (2H, quint. J=7.8 Hz), 2.74 (2H, t, J=7.6 Hz), 3.25 (2H, t, J=6.7 Hz), 4.86 (IH, br.s), 5.09 (2H, s), 7.39 (5H, m), 7.45 (IH, t, J=7.3 Hz), 7.69 (2H, m), and 8.26 (Hi d, J=6.9 Hz) Mass (m/z): 366(Ivf+l) Example 43 2-{5-[(Benzyloxy)carbonylamino]pentyl}-4(3H)-quinazolinone (500 mg, 1.37 mmol) and 10% Pd-C (50 mg) was suspended in THF/MeOH (1 : 1, 20 mL). The mixture was hydrogenated at 3 atm of hydrogen for 8hours. After filtration of Pd-C, the solvent was removed in vacuo. The residue was washed with methanol and ether to give 2-(5-aminopentyl)-4(3H)-quinazolinone (136 mg, 0.59 mmol, 43 %) as colorless powder. i NMR (300MHz, CDC1 3 , δ): 1.36 (4H, s), 1.71 (2H, s), 2.51 (4H, s), 7.44 (Hi d, J=7.0Hz), 7.58 (IH, d, J=8.5Hz), 7.76 (IH, t, J=7.7Hz), and 8.07 (IH, d, J=7.7 Hz) Example 44 To a solution of 2-(5-aminopentyl)-4(3H)-quinazolinone (lOOmg, 0.432mmol) in ethanol (5 mL) benzamide (45.9 mg, 0.432 mmol) was added. After stirring for 30 minutes at room temperature, sodium brohydride was added to the mixture, and the mixture was stirred at room temperature for 4 hours. The reaction mixture was extracted with AcOEt and washed with saturated sodium hydrogen carbonate aqueous solution and brine. The organic layer was dried over MgSO , and the solvent was removed in vacuo. The residual colorless powder was purified with preparative TLC to give 2-(N-benzyl-5-aminopentyl)-4(3H)-quinazolinone (24 mg, 0.075 mmol, 17 %) as colorless powder. 1 H NMR (300MHz, CDC1 3 , δ): 1.50 (2H, m), 1.61 (2H, m), 1.88 (2H, quint, J=7.6Hz), 2.66 (2H, t, J=7.0 Hz), 2.75 (2H, t, J=7.7 Hz), 3.79 (2H, s), 7.25-7.32 (5H, m), 7.45 (Hi t, J=8.0 Hz), 7.68 (IH, t, J=8.1 Hz), 7.76 (IH, t, J=7.0 Hz), and 8.27 (IH, d, J=6.5Hz) Mass (m/z): 322 (Ivf +1) Example 45 The following compounds are prepared in a similar manner to those of Preparation 31, Example 42 and Example 43. (1) 2-(3-aminopropyl)-4(3H)-quinazolinone i NMR (200MHz, DMSO-de, δ): 1.8-2.0 (2H, m), 2.4-3.3 (4H, m), 7.2-8.2 (4H, . m) Mass: 204 (M + +H) (2) 2-(3-aminoethyl)-4(3H)-quinazolinone i NMR (200MHz, DMSO-de, δ): 2.4-2.9 (4H, m), 7.2-8.2 (4H, m) Mass: 190 (Ivf+H) (3) 2-(3-aminomethyl)-4(3H)-quinazolinone 1H NMR (200MHz, DMSO-de, δ): 7.2-8.2 (4H, m) Mass: 176 (Ivf+H) Example 46 The following compounds are prepared in a similar manner to those of Preparation 3_1, Example 42. Example 43 and Example 25. (1) 2-[(lE)-3 -amino-3 -methyl- 1 -butenyl] -4(3 H)-quinazolinone hydrochloride 1H NMR (200MHz, DMSO-de, δ): 1.41 (3H, s), 1.64 (3H, s), 6.50 (IH, d, J = 16Hz), 7.22 (IH, d, J = 16Hz), 7.3-8.3 (4H, m) Mass: 230 (M +H) Example 47 The following compounds are prepared in a similar manner to those of Preparation 31, Example 42. Example 43 and Example 44. ( 1 ) 2- { 3 - [methyl(3 -phenylpropyl)amino]propyl} -4(3H)-quinazolinone 1H NMR (200MHz, DMSO-d 6 , δ): 1.6-2.0 (4H, m), 2.20 (3H, m), 2.2-2.8 (8H, m), 7.0-8.0(8H, m) Mass: 336 (Ivf +H) (2) 2- { 3 -[(4-phenylbutyl)amino]propyl } -4(3H)-quinazolinone 1H NMR (200MHz, DMSO-de, δ): 1.2-1.8 (8H, m), 2.3-2.6 (6H, m), 7.0-7.8 (9H, m), 8.07 (Hid, J = 8Hz) Mass: 336 Ovf+H) (3 ) 2- { 3 -[(3 -phenylpropyl)amino]propyl } -4(3H)-quinazolinone 1H NMR (200MHz, DMSO-de, δ): 1.6-2.0 (4H, m), 2.3-2.7 (8H, m), 7.0-7.8 (8H, m), 8.07 (IH, d, J = 8Hz) Mass: 322 (M + +H) (4) 2-{3-[(2-phenylethyl)amino]propyl}-4(3H)-quinazolinone 1H NMR (200MHz, DMSO-de, δ): 1.6-2. 0(2H, m), 2.3-2.7 (8H, m), 7.0-7.8 (8H, m), 8.08 (lH, d, J = 8Hz) Mass: 308 (Ivf+H) (5) 8-methyl-2-(3-[(3-phenylpropyl)amino]propyl}-4(3H)-quinazolinone 1H NMR (200MHz, DMSO-d 6 , δ): 1.6-2.0 (4H, m), 2.45 (3H, s), 2.4-2.7 (8H, m), 7.0-7.4 (6H, m), 7.62 (IH, d, J = 8Hz), 7.89 (IH, d, J = 8Hz) Mass: 336 (M + +H) (6) 2-{3-[(4-phenoxybenzyl)amino]propyl}-4(3H)-quinazolinone 1H NMR (200MHz, DMSO-de, δ): 1.8-2.0 (2H, m), 2.4-2.8 (4H, m), 3.66 (2H, s), 6.8-7.8 (13H, m), 8.08 (IH, d, J = 8Hz) Mass: 386 (M + +H) (7) 2- { 3 -[(1 , 1 '-biphenyl-3 -ylmethyl)amino]propyl } -4(3H)-quinazolinone 1H NMR (200MHz, DMSO-de, δ): 1.8-2.0 (2H, m), 2.4-2.8 (4H, m), 3J2 (2H, s), 7.2-7.8 (12H, m), 8.06 (IH, d, J = 8Hz) Mass: 370 (Ivf+H) (8) 2- { 3 - [( 1 , 1 '-biphenyl-2-ylmethyl)amino]propyl } -4(3H)-quinazolinone 1H NMR (200MHz, DMSO-de, δ): 1.8-2.0 (2H, m), 2.4-2.8 (4H, m), 3.72 (2H, s), 7.2-7.8 (12H, m), 8.06 (IH, d, J = 8Hz) Mass: 370 (M + +H) (9) 2-{3-[(l, 1 '-biphenyl-4-ylmethyl)amino]propyl}-4(3H)-quinazolinone 5 1H NMR (200MHz, DMSO-d 6 , δ): 1.8-2.0 (2H, m), 2.4-2.9 (4H, m), 3.76 (2H, s), 7.2-7.8 (12H, m), 8.06 (IH, d, J = 8Hz) Mass: 370 (Ivf+H) Example 48 10 The following compounds are prepared in a similar manner to those of Preparation 31, Example 42. Example 43. Example 44 and Example 25. ( 1 ) 2- { 3 - [( lH-benzimidazol-2-ylmethyl)amino]propyl } -4(3H)-quinazolinone dihydrochloride 1H NMR (200MHz, DMSO-d 6 , δ): 2.2-2.9 (4H, m), 4.72 (2H, s), 7.2-7.8 (6H, m), 15 8.0-8.2 (2H, m), 8.2-8.3 (IH, m) Mass: 334 (Ivf+H) Example 49 The following compounds are prepared in a similar manner to that of Preparation 20 31, Example 42. Example 43 and Example 44. (1) 2-[3-(diethylamino)propyl]-4(3H)-quinazolinone 1H NMR (200MHz, DMSO-de, δ): 0.94 (6H, t, J =7.4Hz), 1.8-2.0 (2H, m), 2.3-2.7 (8H, m), 7.44 (IH, t, J = 8.2Hz), 7.57 (IH, d, J = 8.2Hz), 7.76 (IH, d, J = 8.2Hz), 8.06 (IH, d, J = 8.2Hz) 25 Mass: 260 (M + +H) (2) 2-[3-(2,3-dihydro-lH-inden-2-ylamino)propyl]-4(3H)-quinazolinone 1H MR (200MHz, DMSO-de, δ): 1.8-2.0 (2H, m), 2.4-3.0 (9H, m), 6.8-8.0 (8H, m) (3) 2-[3-(2,3-dihydro-lH-inden-2-ylamino)propyl]-8-methyl-4(3H)-quinazolinone 30 1H NMR (200MHz, DMSO-de, δ): 1.8-2.0 (2H,m), 2.51 (3H, s), 2.6-2.8 (4H,m), 7.1-7.3 (4H, m), 7.29 (IH, t, J = 8Hz), 7.62 (IH, d, J = 8Hz), 7.91 (IH, d, J =8Hz) Mass: 334 (M + +H) (4) 2-{3-[2,3-dihydro-lH-inden-2-yl(methyl)amino]propyl}-4(3H)-quinazolinone 1H NMR (200MHz, DMSO-de, δ): 1.8-2.0 (2H, m), 2.18 (3h, s), 2.2-3.3 (9H, m), 35 7.0-7.2 (4H, m), 7.38 (IH, t, J = 8Hz), 7.58 (IH, d, J = 8Hz), 7.78 (Hi t, J = 8Hz), 8.05 (lH, d, J = 8Hz)

Claims: C L AI M S 1. A compound of the formula: wherein R 1 is optionally substituted cyclic amino groups or optionally substituted amino group, R is substituent, n means an integer from 0 to 4, and L is lower alkylene or lower alkenylene, or its prodrug, or their salts. 2. The compound according to claim 1, wherein R 2 is halogen, nitro, amino, acylamino, aryl(lower)alkylamino, lower alkylamino, lower alkyl, lower alkynyl, lower alkoxy, acyl, or cyclic amino group optionally substituted with lower alkyl. 3. The compound according to claim 2, wherein R 1 is (1) cyclic amino group optionally substituted with one or more substituent(s) selected from the group consisting of halogen, cyano, hydroxy, amino, oxo, lower alkyl, lower alkenyl, lower alkynyl, aryl(lower)alkyl, aryl(lower)alkynyl, acyl, lower alkylsulfonyl, optionally substituted heteroaryl and optionally substituted aryl, or (2) amino optionally substituted with 1 or 2 substituent(s) selected from the group consisting of lower alkyl, aryl, heteroaryl(lower)alkyl, aryl(lower)alkoxycarbonyl and aryl(lower)alkyl optionally substituted with aryl or aryloxy. 4. The compound according to claim 3, wherein R 1 is cyclic amino group optionally substituted with optionally substituted heteroaryl or optionally substituted aryl. 5. The compound according to claim 4, wherein R 1 is cyclic amino group with saturated or unsaturated monocyclic group with one or more nitrogen atom(s), which is substituted with optionally substituted heteroaryl or optionally substituted aryl. 6. The compound according to claim 5, wherein R 1 is tetrahydropyridyl, piperidyl or piperazinyl, each of which is substituted with optionally substituted heteroaryl or optionally substituted aryl. 7. The compound according to any one of claims 4, 5 and 6, wherein substituent(s) of optionally substituted heteroaryl is lower alkyl, halogen, cyano or acyl, or substituent(s) of optionally substituted aryl is halogen, cyano, hydroxy, carboxy, nitro, amino, lower alkyl, hydroxy(lower)alkyl, lower alkoxy, lower alkylthio, halo(lower)alkyl, lower alkylamino, acylamino, halo(lower)alkoxy, aryl, aryloxy, or acyl. 8. The compound according to claim 3, wherein R 1 is cyclic amino groups with saturated and unsaturated fused cyclic groups, which is substituted with optionally substituted lower alkyl. 9. The compound according to any one of claims 4, 5, 6, 7 and 8, wherein L is trimethylene. 10. The compound according to claim 9, which is selected from the group consisting of: (l) 5-chloro-2-[3-(4-ρhenyl-3,6-dihydro-l(2H)-ρyridinyl)ρropyl]- 4(3H)-quinazolinone, (2) 2- {3 -[4-(4-hydroxyphenyl)-3 , 6-dihydropyridin- 1 (2H)-yl]propyl } - 4(3H)-quinazolinone, (3 ) 8-methyl-2- (3 -[4-(4-methoxyphenyl)-3 , 6-dihydro- 1 (2H)-ρyridinyl]propyl } - 4(3H)-quinazolinone, (4) 8-chloro-2-{3-[4-(4-fluorophenyl)-3,6-dihydro-l(2H)-pyridinyl]propyl}- 4(3H)-quinazolinone, (5) 8-chloro-2- { ( lE)-3 -[4-(4-fluorophenyl)-3 , 6-dihydro- 1 (2H)-pyridinyl]- 1 -propenyl} - 4(3H)-quinazolinone, (6) 8-Chloro-2- { [4-(4-pyridinyl)-3 , 6-dihydro- 1 (2H)-pyridinyl] propyl} - 4(3H)-quinazolinone, (7) 2- {3 -[4-(4-chlorophenyl)- 1 -piperazinyljpropyl } -4(3H)-quinazolinone, (8) 2-{3-[4-(4-pyridyl)-l-piperazinyl]propyl}-4(3H)-quinazolinone, (9) 2-[3-(l,4,5,6-Tetrahydrobenzo[f]isoquinolin-3(2H)-yl)propyl]- 4(3H)-quinazolinone, and (10) 8-methyl-2-[3-(l,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)propyl]- 4(3H)-quinazolinone. 11. A process for preparing a compound of the formula: wherein R 1 is optionally substituted cyclic amino groups or optionally substituted amino group, R 2 is substituent, n means an integer from 0 to 4, and L is lower alkylene or lower alkenylene, or its prodrug, or their salts, which comprises, (1) reacting the formyl group of the compound (II) of the formula: or its aminal derivative, or their salt, and imino group of the compound (IV) of the formula: R x -H or its salt, in the presence of a reducing agent to provide a compound of the formula: or its salt, in the above formulae, R 1 , R 2 , n and L are each as defined above, and L 1 is lower alkylene or lower alkenylene delating a methylene group from the end of the one defined in L, or (2) subjecting the compound (III) of the following formula: or its salt, to cyclization reaction in the presence of base to provide a compound of the formula: or its salt, in the above formurae, R ,ι , R , n and L are each as defined above. 12. A pharmaceutically composition comprising a compound of the formula: wherein R 1 is optionally substituted cyclic amino groups or optionally substituted amino group, R 2 is substituent, n means an integer from 0 to 4, and L is lower alkylene or lower alkenylene, or its prodrug, or their pharmaceutically acceptable salts, and a pharmaceutically acceptable carrier, wherein said compound is present in an amount effective for inhibiting PARP activity. 13. The pharmaceutical composition of claim 12 for treating or preventing diseases ascribed by NMD A- and NO-induced toxicity. 14. The pharmaceutical composition of claim 12 for extending the lifespan or proliferative capacity of cells or altering gene expression of senescent cells 15. The pharmaceutical composition of claim 13 for treating or preventing tissue damage resulting from cell damage or death due to necrosis or apoptosis; neural tissue damage resulting from ischemia and reperfusion injury, neurological disorders and neurodegenerative diseases; neurodegenerative diseases; head trauma; stroke; Alzheimer's disease; Perkinson's disease; epilepsy; Amyotrophic Lateral Scleosis (ALS); Huntington's disease; schizopherenia; chronic pain; ischemia and nloss following hypoxia; hypoglycemia; ischemia; trauma; nervous insult; previously ischemic heart or skeleton muscle tissue; radiosensitizing hypoxic tumor cells; tumor cells from recovering from potentially lethal damage of DNA after radiation therapy; skin aging; atheroscleosis; osteoarthritis; osteoporosis; muscular dystrophy; degenerative diseases of skeletal muscle involving replicative senescence; age-related macular degeneration; immune senescence; ATDS; and other immune senescencediseases; inflammatory bowel disorders (e.g, colitis); arthritis; diabetes; endotoxic shock; septic shock; and tumor. 16. A method of inhibiting PARP activity comprising administering a compound of the formula: wherein R 1 is optionally substituted cyclic amino groups or optionally substituted amino group, R 2 is substituent, n means an integer from 0 to 4, and L is lower alkylene or lower alkenylene, or its prodrug, or their pharmaceutically acceptable salts, and a pharmaceutically acceptable carrier, wherein said compound is present in an amount effective for inhibiting PARP activity.

Inventors: HATTORI KOUJI, ISHIDA JUNYA, IWASHITA AKINORI, KAMIJO KAZUNORI, KIDO YOSHIYUKI, MATSUOKA NOBUYA, MIYAKE HIROSHI, NAKANISHI ISAO, OHKUBO MITSURU, YAMAMOTO HIROFUMI, YAMAZAKI SHUNJI, HATTORI, KOUJI, ISHIDA, JUNYA, IWASHITA, AKINORI, KAMIJO, KAZUNORI, KIDO, YOSHIYUKI, MATSUOKA, NOBUYA, MIYAKE, HIROSHI, NAKANISHI, ISAO, OHKUBO, MITSURU, YAMAMOTO, HIROFUMI, YAMAZAKI, SHUNJI
Applicants: FUJISAWA PHARMACEUTICAL CO, HATTORI KOUJI, ISHIDA JUNYA, IWASHITA AKINORI, KAMIJO KAZUNORI, KIDO YOSHIYUKI, MATSUOKA NOBUYA, MIYAKE HIROSHI, NAKANISHI ISAO, OHKUBO MITSURU, YAMAMOTO HIROFUMI, YAMAZAKI SHUNJI, FUJISAWA PHARMACEUTICAL CO., LTD., HATTORI, KOUJI, ISHIDA, JUNYA, IWASHITA, AKINORI, KAMIJO, KAZUNORI, KIDO, YOSHIYUKI, MATSUOKA, NOBUYA, MIYAKE, HIROSHI, NAKANISHI, ISAO, OHKUBO, MITSURU, YAMAMOTO, HIROFUMI, YAMAZAKI, SHUNJI
Application year: 2001
Main classification: C07D239
IPC codes: A61K31, A61P1, A61P3, A61P9, A61P17, A61P19, A61P21, A61P25, A61P27, A61P31, A61P35, A61P37, A61P39, A61P43, C07D239, C07D401, C07D403, C07D405, C07D409, C07D413, C07D417, C07D471, C07D487